RU2577858C2 - NEW PYRROLO[3,2-d]PYRIMIDIN-4-ONE DERIVATIVES AND USING THEM IN THERAPY - Google Patents

Abstract

FIELD: medicine, pharmaceutics.

SUBSTANCE: in formula

at least one of X and Y represents S, and the other represents O; L represents C_1-7alkylene optionally including a heteroatom specified in O, wherein the above alkylene is optionally substituted by one or more substitutes independently specified in OH, C_1-6alkyl and C_1-6alkoxy; R¹ represents hydrogen or 1) a partially substituted 6-merous ring containing one heteroatom specified in N, and optionally containing a carbonyl group; or 2) an aromatic ring system specified in: phenyl, a monocyclic 5- or 6-merous heteroaromatic ring structure containing 1-2 heteroatoms specified in N, and a bicyclic heteroaromatic ring structure containing a 5- or 6-merous heterocycle containing 1-2 heteroatoms specified in N, wherein the above heterocycle is condensed with a benzene ring, wherein the above aromatic ring system is optionally substituted by one or more substitutes optionally specified in halogen, OH, C_1-7alkyl, C_1-7alkoxy; wherein the above alkoxy is optionally additionally substituted by C_1-6alkoxy, and wherein the above alkyl is optionally additionally substituted by hydroxy or C_1-6alkoxy; R¹² represents hydrogen; provided the above compound is other than 1-(2-isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d]pyrimidin-4-one.

EFFECT: invention refers to the new compounds of formula (I), their tautomers or their pharmaceutically acceptable salts, which possess the properties of myeloperoxidase (MPO) inhibitors and are especially effective in treating or preventing neuroinflammatory, cardiovascular and respiratory disorders.

22 cl, 1 tbl, 33 ex

Description

Field of Invention

The present invention relates to new derivatives of pyrrolo [3,2-d] pyrimidin-4-one, to methods for their preparation, to compositions containing them, and to their use in therapy.

State of the art

Myeloperoxidase (MPO) is a heme-containing enzyme found mainly in polymorphonuclear leukocytes (PMNL). MPO is one of the members of the diverse protein family of mammalian peroxidases, which also includes eosinophil peroxidase, thyroid peroxidase, saliva peroxidase, lactoperoxidase, prostaglandin H synthase and others. A mature enzyme is a dimer of identical parts. Each part of the molecule contains covalently bonded to one that exhibits unusual spectral properties responsible for the characteristic green color of MPO. Cleavage of the disulfide bridge connecting the two parts of MPO gives a hemi-enzyme that exhibits spectral and catalytic properties indistinguishable from the properties of the intact enzyme. This enzyme uses hydrogen peroxide to oxidize chloride to hypochlorous acid. Other halides and pseudohalogen ides (such as thiocyanate) are also physiological substrates of MPO.

PMNLs are especially important for fighting infections. These cells contain MPO with a well-proven bactericidal effect. PMNLs act nonspecifically by phagocytosis to absorb microorganisms, include them in vacuoles, called phagosomes, which merge with granules containing myeloperoxidase to form phagolysosomes. In phagolysosomes, the enzymatic activity of myeloperoxidase leads to the formation of hypochlorous acid, a potent bactericidal compound. Hypochlorous acid itself is an oxidizing agent and reacts most strongly with thiols and thioesters, but also converts amines to chloramines and chlorinates aromatic amino acids. Macrophages are large phagocytic cells that, like PMNL, are capable of phagocytizing microorganisms. Macrophages can generate hydrogen peroxide and, upon activation, also produce myeloperoxidase. MPO and hydrogen peroxide can also be released externally from cells, where a reaction with chloride can induce damage to adjacent tissue.

The association of myeloperoxidase activity with the disease was implied in neurological diseases with a neuroinflammatory reaction, including multiple sclerosis, Alzheimer's disease, Parkinson's disease and stroke, as well as in other inflammatory diseases or conditions such as asthma, chronic obstructive pulmonary disease, cystic fibrosis, atherosclerosis, inflammatory disease bowel, glomerular kidney damage, and rheumatoid arthritis. It has also been suggested that lung cancer is associated with high levels of MPO.

Multiple Sclerosis (PC)

MPO-positive cells are present in large numbers in the bloodstream and in tissue undergoing inflammation. More specifically, macrophages and microglia containing MPO were confirmed in the central nervous system during the disease: multiple sclerosis (Nagra RM, et al. Journal of Neuroimmunology 1997; 78 (1-2): 97-107), Parkinson's disease (Choi DK. et al. J. Neurosci. 2005; 25 (28): 6594-600) and Alzheimer's disease (Green PS. et al. Journal of Neurochemistry. 2004; 90 (3): 724-33). It is assumed that some aspects of chronic ongoing inflammation lead to very severe destruction, where agents from MPO reactions play an important role.

This enzyme is released extracellularly, as well as into phagolysosomes in neutrophils (Hampton MB, Kettle AJ, Winterbourn CC. Blood 1998; 92 (9): 3007-17). A prerequisite for MPO activity is the presence of hydrogen peroxide generated by nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase) and subsequent superoxide dismutation. The oxidized enzyme is able to use many different substrates, of which chloride is best recognized. In this reaction, a strong non-radical oxidizing agent is formed - hypochlorous acid (HOCl). HOCl very efficiently oxidizes sulfur-containing amino acids such as cysteine and methionine (Peskin AV, Winterbourn CC. Free Radical Biology and Medicine 2001; 30 (5); 572-9). It also forms chloramines with amino groups in both proteins and other biomolecules (Peskin AV. Et al. Free Radical Biology and Medicine 2004; 37 (10): 1622-30). It chlorinates phenols (such as tyrosine) (Hazen SL. Et al. Mass Free Radical Biology and Medicine 1997; 23 (6): 909-16) and unsaturated bonds in lipids (Albert CJ. Et al. J. Biol. Chem. 2001; 276 (26): 23733-41), oxidizes the centers with iron (Rosen H, Klebanoff SJ. Journal of Biological Chemistry 1982; 257 (22): 13731-354) and cross-binds proteins (Fu X, Mueller DM, Heinecke JW Biochemistry 2002; 41 (4): 1293-301).

Proteolytic cascades are involved both in the penetration of cells through the blood-brain barrier (BBB) and in the destruction of the BBB, myelin and nerve cells (Cuzner ML, Opdenakker G. Journal of Neuroimmunology 1999; 94 (1-2): 1-14; Yong VW. et al. Nature Reviews Neuroscience 2001; 2 (7): 502-11.). The activation of matrix metalloproteinases (MPM) can be carried out through the action of proteases located higher in the cascade, as well as through the oxidation of the disulfide bridge (Fu X. et al. J. Biol. Chem. 2001; 276 (44): 41279-87; Gu Z. et al. Science 2002; 297 (5584): 1186-90). This oxidation can be either nitrosylation or HOCl mediated oxidation. Both reactions may be due to the activity of MPO. Several reports suggested the role of MPM in general and, in particular, MPM-9 in influencing cell infiltration, as well as in tissue damage (destruction of the BBB and demyelination), both in PC and EAE (for a review see Yong VW. et al. above). The importance of these specific types of mechanisms in PC comes from studies where increased activity and the presence of proteases were identified in brain tissue and cerebrospinal fluid (CSF) in PC. Supporting data was also obtained by conducting EAE studies with mice deficient in certain proteases, for which they involved involvement in PC pathology, or by using pharmacological approaches.

Demyelination is believed to be dependent on cytotoxic T cells and toxic products generated by activated phagocytes (Lassmann H.J Neurol Neurosurg Psychiatry 2003; 74 (6): 695-7). Axon loss is thus affected by proteases and reactive intermediates of oxygen and nitrogen. When MPO is present, it will obviously have the ability to both activate proteases (directly, as well as through the abolition of inhibition, affecting protease inhibitors) and the generation of reactive compounds.

Chronic Obstructive Pulmonary Disease (COPD)

Chronic obstructive pulmonary disease (COPD) is a painful condition characterized by airflow restriction that is not completely reversible. The restriction of air flow is usually both progressive and associated with an abnormal inflammatory response of the lungs to toxic particles or gases. COPD is an important public health problem. In the United States, it is the fourth leading cause of chronic morbidity and mortality, and in 2020 is projected to take 5th place in the world as the most burdensome disease. In the UK, the spread of COPD is 1.7% in men and 1.4% in women. COPD covers the severity of the disease from moderate to very severe, and the cost of treatment increases rapidly with increasing severity.

MPO levels in sputum and bronchoalveolar secretions (BAS) are significantly higher in patients with COPD than in normal non-smoking control patients (Keatings VM, Barnes PJ Am J Respir Crit Care Med 1997; 155: 449-453; Pesci, A. et al. Eur Respir J 1998: 12: 380-386). MPO levels are further increased during exacerbations of the disease (Fiorini G. et al. Biomedicine & Pharmacotherapy 2000; 54: 274-278; Crooks S.W. et al. European Respiratory Journal. 15 (2): 274-80, 2000). The role of MPO is probably more important for exacerbations of COPD (Sharon S.D. et al. Am J Respir Crit Care Med. 2001: 163: 349-355).

In addition to the destructive ability of MPO, there is a strong clinical association with vascular disease (Baldus S. et al. Circulation 2003: 108: 1440-5). Dysfunctional MPO polymorphisms are associated with a reduced risk of mortality from coronary artery disease (Nikpoor B. et al. Am Heart J 2001; 142: 336), and patients with high serum MPO levels have an increased risk of acute coronary syndrome. The effects of MPO on vascular disease can extend to COPD, as there is strong evidence that pulmonary vessels are one of the earliest lung lesions in smokers. They described striking changes in the intima of the arteries of the lungs, which show a relationship with the dose of smoking (Hale K.A., Niewoehner D.E., Cosio M.G. Am Rev Resp Dis 1980: 122: 273-8). The physiological function of MPO is associated with innate host defense. This role, however, is not critical since in most cases, patients with MPO deficiency have relatively harmless symptoms (Parry MF et al. Ann Int Med. 1981; 95: 293-301, Yang, KD, Hill, HR Pediatr Infect Dis J. 2001: 20: 889-900). In summary, there is much evidence that elevated MPO levels in COPD can contribute to the disease through several mechanisms. Therefore, it can be expected that a selective MPO inhibitor will alleviate both acute and chronic inflammatory aspects of COPD and may weaken the development of emphysema.

Atherosclerosis

An MPO inhibitor should reduce the susceptibility to atherosclerosis and / or the susceptibility of existing atherosclerotic lesions and, thereby, reduce the risk of acute myocardial infarction, unstable angina or stroke. Several data groups confirm the role of MPO in atherosclerosis. MPO is expressed in the shoulder regions and in the necrotic nucleus of human atherosclerotic lesions, and the active enzyme was isolated from autopsy samples of human lesions (Daugherty, A. et al. (1994) J Clin Invest 94 (1): 437-44). An increased number of macrophages expressing MPO was demonstrated in human lesions associated with erosion and rupture, compared with fatty layers, which indicates the special role of MPO in acute coronary syndromes (Sugiyama, S. et al. (2001) Am J Pathol 158 ( 3): 879-91). Patients with established coronary artery disease have higher levels of MPO in plasma and in white blood cells than healthy control patients (Zhang, R. et al. (2001) Jama 286 (17): 2136-42). In addition, in two large prospective studies, plasma MPO levels predicted the risk of future coronary complications or revascularization (Baldus, S. et al. (2003) Circulation 108 (12): 1440-5; Brennan, M. et al. (2003 ) N EngI J Med 349 (17): 1595-604). General MPO deficiency in humans has a frequency of 1 in 2000–4000 individuals. These individuals generally look healthy, but have reported several cases of serious Candida infection. Interestingly, a person with a lack of MPO is less susceptible to cardiovascular disease than controls with normal levels of MPO (Kutter, D. et al. (2000) Acta Haematol 104 (1)). Polymorphism in the MPO promoter affects expression, which leads to the appearance of individuals with strong and weak MPO expression. In three different studies, a strong expression genotype was associated with an increased risk of cardiovascular disease (Nikpoor, B. et al. (2001) Am Heart J 142 (2): 336-9; Makela, R „PJ Karhunen, et al. ( 2003) Lab Invest 83 (7): 919-25; Asselbergs, F. W, et al. (2004) Am J Med 116 (6): 429-30). Data collected over the past ten years indicate that the pro-atherogenic effects of MPO include the oxidation of lipoproteins, the induction of endothelial dysfunction through nitric oxide intake, and the destabilization of atherosclerotic lesions by activation of proteases (Nicholls, SJ and SL Hazen (2005) Arterioscler Thromb Vase Biol 25 (6): 1102-11). Recently, several studies have focused on nitro- and chlortyrosine modifications of low-density lipoproteins (LDL) and high-density lipoproteins (HDL). Since in vivo chlorothyrosine modifications can only be generated by hypochlorous acid produced by MPO, these modifications are considered as specific markers of MPO activity (Hazen, S. L. and J. W. Heinecke (1997) J Clin Invest 99 (9): 2075-81). LDL particles exposed to MPO in vitro become aggregated, resulting in easier absorption through macrophage phagocytic receptors and the formation of foam cells (Hazell, L. J. and R. Stocker (1993) Biochem J 290 (Pt 1): 165-72). Chlortyrosine modification of apoA1, the main HDL cholesterol apolipoprotein, leads to weakened cholesterol-acceptor function (Bergt, C., S. et al. (2004) Proc NatI Acad Sci USA; Zheng, L. et al. (2004) J Clin Invest 114 (4): 529-41). Systematic studies of these mechanisms have shown that in plasma MPO binds and is transported with apoA1. In addition, MPO specifically targets those tyrosine apoA1 residues that physically interact with the macrophage cassette transporter ABCA1 during the outflow of cholesterol from the macrophage (Bergt, C. et al. (2004) J Biol Chem 279 (9): 7856-66; Shao , B. et al. (2005) J Biol Chem 280 (7): 5983-93; Zheng et al. (2005) J Biol Chem 280 (1): 38-47). Thus, MPO, apparently, has a double aggravating role in atherosclerotic lesions, that is, it increases lipid accumulation through aggregation of LDL particles and reduces cholesterol reverse transport by attacking HDL apoA1 protein.

1-β-O-Ribofuranosyl-2-oxopyrrolo [3,2-d] pyrimidin-4 (3H, 5H) -thion and 1- (2,3,5-tri-O-benzoyl-1-β-G- ribofuranosyl) -2-oxopyrrolo [3,2-d] pyrimidin-4 (3H, 5H) -thion

disclosed in J. Heterocyclic Chemistry, 1992, 29, 343-354. No pharmacological activity is attributed to these compounds. 5,7-Dimercapto-1,4,6-triazainden S

disclosed in Chem. Pharm. Bull., 1964, 12, 1030-1042 and Japanese Patent JP 02160235 A2. No pharmacological activity is attributed to this compound.

The present invention discloses novel pyrrolo [3,2-d] pyrimidin-4-one derivatives that unexpectedly exhibit useful properties as inhibitors of the MPO enzyme. These compounds may also show selectivity for related enzymes, such as lactoperoxidase (LPO) and thyroid peroxidase (PSA).

Description of the election

The present invention provides compounds of formula (I)

Where:

at least one of X and Y represents S, and the other

represent O or S;

L is a direct bond or C _1-7 alkylene, optionally including a heteroatom selected from O, S (O) _n and NR ⁶ , wherein said alkylene may include one or two carbon-carbon double bonds, and wherein said alkylene is optionally substituted with one or more than one substituent independently selected from OH, halogen, CN and NR ⁴ R ⁵ , C _1-6 alkyl, and C _1-6 alkoxy, wherein said alkoxy optionally includes carbonyl adjacent to oxygen;

n is an integer of 0, 1 or 2;

R ¹ represents hydrogen or

1) a saturated or partially unsaturated 3-7 membered ring, possibly including one or two heteroatoms independently selected from O, N and S, and possibly including a carbonyl group, possibly substituted by one or more than one substituent independently selected from halogen, SO ₂ R ⁹ , SO ₂ NR ⁹ R ¹⁰ , OH, C _1-7 alkyl, C _1-7 alkoxy, CN, CONR ² R ³ , NR ² COR ³ and COR ³ , wherein said alkoxy is optionally further substituted with C _1-7 alkoxy and optionally includes carbonyl adjacent to oxygen, and wherein said alkyl is optionally further substituted with hydroxy or C _1-6 alkoxy, and wherein alkyl or alkoxy may optionally include carbonyl adjacent to oxygen, or at any position in the alkyl;

or

2) an aromatic ring system selected from phenyl, biphenyl, naphthyl or a monocyclic or bicyclic heteroaromatic ring structure containing 1-3 heteroatoms independently selected from O, N and S, where the specified aromatic ring system is possibly substituted by one or more than one substituent, independently selected from halogen, SO ₂ R ⁹ , SO ₂ NR ⁹ R ¹⁰ , OH, C _1-7 alkyl, C _1-7 alkoxy, CN, CONR ² R ³ , NR ² COR ³ and COR ³ ; wherein said alkoxy is optionally further substituted with C _1-6 alkoxy and possibly includes a carbonyl adjacent to oxygen, and where said alkyl is optionally further substituted with hydroxy or C _1-6 alkoxy, and where said alkyl or alkoxy optionally includes carbonyl adjacent to oxygen, or in any position in alkyl;

R ¹² represents hydrogen or halogen, or carbon, possibly substituted by one to three halogen atoms;

in each case, R ² , R ³ , R ⁴ , R ⁵ , R ⁶ , R ⁹ and R ¹⁰ independently represent hydrogen, C _1-6 alkyl or C _1-6 alkoxy, wherein said alkoxy optionally includes carbonyl adjacent to oxygen, wherein said alkyl is optionally further substituted with halogen, C _1-6 alkoxy, CHO, C _2-6 alkanoyl, OH, CONR ⁷ R ⁸ and NR ⁷ OR ⁸ ;

or each group NR ² R ³ , NR ⁴ R ⁵ and NR ⁹ R ¹⁰ independently represents a 5-7 membered saturated azacyclic ring, optionally including one additional heteroatom selected from O, S and NR ¹¹ , wherein said ring is optionally further substituted halogen, C _1-6 alkoxy, CHO, C _2-6 alkanoyl, OH, CONR ⁷ R ⁸ and NR ⁷ COR ⁸ ;

in each case, R ⁷ , R ⁸ and R ¹¹ independently represent hydrogen or C _1-6 alkyl, or the group NR ⁷ R ⁸ represents a 5-7 membered saturated azacyclic ring, optionally including one additional heteroatom selected from O, S and NR ¹¹ ;

and pharmaceutically acceptable salts thereof;

with the proviso that the compounds 1-β-D-ribofuranosyl-2-oxopyrrolo [3,2-d] pyrimidin-4 (3H, 5H) -thion, 1- (2,3,5-tri-O-benzoyl-1 β-D-ribofuranosyl) -2-oxopyrrolo [3,2-d] pyrimidin-4 (3H, 5H) -thione and 5,7-dimercapto-1,4,6-triazaindene are excluded from the scope of protection.

The compounds of formula (I) may exist in enantiomeric forms. It should be understood that all enantiomers, diastereomers, racemates, tautomers and mixtures thereof are included in the scope of the invention.

The compounds of formula (I) may exist in tautomeric forms. All such tautomers and mixtures of tautomers are included in the scope of the present invention.

Unless otherwise indicated, the term “C _1-6 alkyl”, referred to herein, means a straight or branched chain alkyl group having from 1 to 6 carbon atoms. Examples of such groups include, but are not limited to methyl, ethyl, 1-propyl, n-butyl, iso-butyl, mpem-butyl, pentyl and hexyl. The term _"C1-7 alkyl" should be interpreted similarly.

Unless otherwise specified, the term “C _1-7 alkylene”, referred to herein, means a straight or branched chain alkyl group having from 1 to 7 carbon atoms, having two free valencies. Examples of such groups include, but are not limited to, methylene, ethylene, propylene, hexamethylene and ethylene. The term “C _1-3 alkylene” should be interpreted in a similar manner.

Unless otherwise indicated, the term “C _1-6 alkoxy”, referred to herein, means a straight or branched chain alkoxy group having from 1 to 6 carbon atoms. Examples of such groups include, but are not limited to, methoxy, ethoxy, 1-propoxy, 2-propoxy (iso-propoxy), mpem-butoxy, and pentoxy. The term “C _1-7 alkoxy” should be interpreted in a similar manner.

Unless otherwise indicated, the term “C _2-6 alkanoyl” as referred to herein means a straight or branched chain alkyl group having from 1 to 5 carbon atoms with a possible arrangement of the carbonyl group on the alkyl group. Examples of such groups include, but are not limited to, acetyl, propionyl, and pivaloyl.

Unless otherwise indicated, the term "halogen", which is referred to here, means fluoro, chloro, bromo and iodine.

Examples of a saturated or partially unsaturated 3-7 membered ring, optionally including one or two heteroatoms independently selected from O, N and S, and optionally including a carbonyl group, include cyclopropane, cyclopentane, cyclohexane, cyclohexene, cyclopentanone, tetrahydrofuran, pyrrolidine, piperidine , tetrahydropyridine, morpholinme, piperazine, pyrrolidinone and piperidinone, but not limited to.

Examples of a monocyclic or bicyclic heteroaromatic ring structure containing 1 to 3 heteroatoms independently selected from O, N and S include furan, thiophene, pyrrole, oxazole, isoxazole, thiazole, imidazole, pyrazole, triazole, tetrazole, pyridine, pyrazine, pyrimidine, pyridazine, benzofuran, indole, isoindole and benzimidazole, but not limited to.

Examples of a 5-7 membered saturated azacyclic ring, optionally including one additional heteroatom selected from O, S and NR, include, but are not limited to, pyrrolidine, piperidine, piperazine, morpholine and thiomorpholine.

In the definition of L, “C _1-7 alkylene; optionally including a heteroatom selected from O, S (O) _n and NR ⁶ ; where the specified alkylene possibly includes one or two carbon-carbon double bonds "encompasses the structure of a saturated or unsaturated straight or branched chain of 1-7 carbon atoms having two free valencies, in which any two carbon atoms linked by single bonds, possibly separated by O, S or NR ⁶ . This definition thus includes, for example, methylene, ethylene, propylene, hexamethylene, ethylene, —CH ₂ = CH ₂ -, —CH ₂ CH = CH — CH ₂ -, —CH (CH ₃ ) = CH ₂ -, -CH ₂ = CH ₂ -CH ₂ O-, -CH ₂ O-, -CH ₂ CH ₂ O-CH ₂ -, -CH ₂ CH ₂ O-CH ₂ -CH ₂ -, -CH ₂ CH ₂ S- and -CH ₂ CH ₂ NR ⁶ -.

In one embodiment, R ¹ represents hydrogen.

In another embodiment, X represents S, and Y represents O.

In yet another embodiment, Y represents S, and X represents O.

In yet another embodiment, L is a direct bond or is C _1-7 alkylene, optionally including a heteroatom selected from O, S (O) _n and NR ⁶ , wherein said alkylene optionally includes one or two carbon-carbon double bonds, and wherein said alkylene is optionally substituted with one or more substituents independently selected from OH, C _1-6 alkoxy, halogen, CN and NR ⁴ R ⁵ .

In yet another embodiment, L is a direct bond or is C _1-7 alkylene optionally substituted with one or more substituents independently selected from OH, C _1-6 alkoxy, halogen, CN, and NR ⁴ R ⁵ .

In yet another embodiment, L is a direct bond or is C _1-7 alkylene, optionally substituted with one or more C _1-6 alkoxy.

In yet another embodiment, L is a direct bond or is C _1-3 alkylene, wherein said alkylene is optionally substituted with one or more substituents independently selected from OH, C _1-6 alkoxy, halogen, CN and NR ⁴ R ⁵ .

In yet another embodiment, L represents C _1-3 alkylene wherein said alkylene is optionally substituted with one or more than one C _1-6 alkoxy.

In yet another embodiment, L is a direct bond or is optionally substituted methylene (—CH ₂ -).

In yet another embodiment, L represents a direct bond or represents optionally substituted ethylene (-CH ₂ CH ₂ -).

In yet another embodiment, R ¹ is a saturated or partially unsaturated 3-7 membered ring, optionally including one or two heteroatoms independently selected from O, N and S, and optionally including a carbonyl group, wherein said ring is optionally substituted with one or more than one substituent independently selected from halogen, SO ₂ R ⁹ , SC ₂ NR ⁹ R ¹⁰ , OH, C _1-6 alkyl, C _1-6 alkoxy, CN, CONR ² R ³ , NR ² OR ³ and COR ³ , wherein said alkoxy is optionally further substituted by C _1-6 alkoxy, and wherein said alkyl is optionally further substituted by hydroxy or C _1-6 and Cox.

In yet another embodiment, R ¹ is a saturated or partially unsaturated 3-7 membered ring, optionally including one or two heteroatoms independently selected from O, N and S, and optionally including a carbonyl group, wherein said ring is optionally substituted with one or more than one substituent independently selected from halogen, C _1-6 alkyl and C _1-6 alkoxy, wherein said alkoxy is optionally further substituted with C _1-6 alkoxy.

In yet another embodiment, R ¹ is an aromatic ring system selected from phenyl, biphenyl, naphthyl, or a monocyclic or bicyclic heteroaromatic ring structure containing 1-3 heteroatoms independently selected from O, N and S, wherein said aromatic ring is optionally substituted one or more than one substituent independently selected from halogen, SO ₂ R ⁹ , SO ₂ NR ⁹ R ¹⁰ , OH, C _1-6 alkyl, C _1-6 alkoxy, CN, CONR ² R ³ , NR ² COR ³ and COR ³ , wherein said alkoxy is optionally further substituted with C _1-6 alkoxy, and wherein said alkyl optionally further substituted with hydroxy or C _1-6 alkoxy.

In yet another embodiment, R ¹ is an aromatic ring system selected from phenyl, biphenyl, naphthyl, or a five- or six-membered heteroaromatic ring containing 1-3 heteroatoms independently selected from O, N, and S, wherein said aromatic ring is optionally substituted one or more substituents independently selected from halogen, C _1-6 alkyl and C _1-6 alkoxy, wherein said alkoxy is optionally further substituted with C _1-6 alkoxy.

In yet another embodiment, R ¹ is optionally substituted phenyl.

In yet another embodiment, R ¹ is optionally substituted pyridyl.

In yet another embodiment, L represents C _1-7 alkylene and R ¹ is H.

In yet another embodiment, L is a possibly substituted C _1-3 alkylene, and R ¹ is a saturated or partially unsaturated 3-7 membered ring, optionally including one or two heteroatoms independently selected from O, N, and S, and optionally comprising a carbonyl group, wherein said ring is optionally substituted with one or more substituents independently selected from halogen, SO ₂ R ⁹ , SO ₂ NR ⁹ R ¹⁰ , OH, C _1-6 alkyl, C _1-6 alkoxy, CN, CONR ² R ³ , NR ² COR ³ and COR ³ , wherein said alkoxy is optionally further substituted with C _1-6 alkoxy, and where said al the keel is optionally further substituted with hydroxy or C _1-6 alkoxy.

In yet another embodiment, L is a possibly substituted C _1-3 alkylene, and R ¹ is a saturated or partially unsaturated 3-7 membered ring, optionally including one or two heteroatoms independently selected from O, N, and S, and optionally comprising a carbonyl group, wherein said ring is optionally substituted with one or more substituents independently selected from halogen, C _1-6 alkyl and C _1-6 alkoxy, wherein said alkoxy is optionally further substituted with C _1-6 alkoxy.

In yet another embodiment, L is a possibly substituted C _1-3 alkylene, and R ¹ is an aromatic ring system selected from phenyl, biphenyl, naphthyl, or a five or six membered heteroaromatic ring containing 1-3 heteroatoms independently selected from O, N and S; wherein said aromatic ring is optionally substituted with one or more substituents independently selected from halogen, SO ₂ R ⁹ , SO ₂ NR ⁹ R ¹⁰ , OH, C _1-6 alkyl, C _1-6 alkoxy, CN, CONR ² R ³ , NR ² COR ³ and COR ³ , wherein said alkoxy is optionally further substituted with C _1-6 alkoxy, and where said alkyl is optionally further substituted with hydroxy or C _1-6 alkoxy.

In yet another embodiment, L is a possibly substituted C _1-3 alkylene, and R ¹ is an aromatic ring system selected from phenyl, biphenyl, naphthyl, or a five or six membered heteroaromatic ring containing 1-3 heteroatoms independently selected from O, N and S, wherein said aromatic ring is optionally substituted with one or more substituents independently selected from halogen, C _1-6 alkyl and C _1-6 alkoxy, wherein said alkoxy is optionally further substituted with C _1-6 alkoxy.

In yet another embodiment X represents S, Y represents O, L represents a possibly substituted C _1-3 alkylene, and R ¹ represents a possibly substituted phenyl.

In yet another embodiment X represents S, Y represents O, L represents a possibly substituted C _1-3 alkylene, and R ¹ represents a possibly substituted pyridyl.

In yet another embodiment, X represents S, Y represents O, L represents C _1-3 alkylene, substituted C _1-3 alkoxy, and R ¹ represents hydrogen.

Specific compounds of this invention include:

1-butyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1-isobutyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1- (pyridin-2-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1- (2-fluoro-benzyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1- [2- (2-methoxyethoxy) -3-propoxybenzyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1- (6-ethoxy-pyridin-2-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1-piperidin-3-ylmethyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1-butyl-4-thioxo-1,3,4,5-tetrahydro-2H-pyrrolo [3,2-d] pyrimidin-2-one;

1- (2-isopropoxyethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1- (2-methoxy-2-methylpropyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1- (2-ethoxy-2-methylpropyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1- (piperidin-4-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1 - [(1-methylpiperidin-3-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1- [2-hydroxy-2- (4-methoxyphenyl) ethyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1- (2-methoxybenzyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1- (3-methoxybenzyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1- (2,4-dimethoxybenzyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1 - [(3-chloropyridin-2-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-OH;

1 - {[3- (2-ethoxyethoxy) pyridin-2-yl] methyl} -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1 - [(6-oxo-1,6-dihydropyridin-2-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1- (1H-indol-3-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1- (1H-benzimidazol-2-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1 - [(5-chloro-1H-indol-2-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1 - [(5-fluoro-1H-indol-2-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1- (1H-indol-6-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1- (1H-indol-5-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1 - [(5-fluoro-1H-indol-3-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1 (1H-imidazol-5-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1 (1H-imidazol-2-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1 - [(5-chloro-1H-benzimidazol-2-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

1 - [(4,5-dimethyl-1H-benzimidazol-2-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;

7-bromo-1-isobutyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one; and

1- (3-chlorophenyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

and their pharmaceutically acceptable salts.

Another aspect of the present invention is the use of new compounds of formula (I) as a medicine.

Another aspect of the present invention is the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of diseases or conditions in which inhibition of the MPO enzyme is useful.

According to another aspect of the present invention, there is provided the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of neuroinflammatory disorders, cardiovascular atherosclerotic disorders and atherosclerotic cerebrovascular disorders, peripheral arterial diseases and respiratory diseases such as chronic obstructive lung disease.

According to yet another aspect of the present invention, there is provided the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prevention of multiple sclerosis. Treatment may include slowing the progression of the disease.

According to yet another aspect of the present invention, there is provided the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prevention of atherosclerosis by preventing and / or reducing the formation of new atherosclerotic lesions or plaques and / or by preventing or slowing down the development of existing lesions and plaques.

According to yet another aspect of the present invention, there is provided the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prevention of atherosclerosis by altering the composition of the plaques to reduce the risk of plaque detachment and atherothrombotic complications.

According to yet another aspect of the present invention, there is provided the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prevention of respiratory disorders such as chronic obstructive pulmonary disease. Treatment may include slowing the progression of the disease.

The present invention also provides a method for treating or reducing the risk of diseases or conditions in which inhibition of the MPO enzyme is useful, comprising administering to a subject suffering from said disease or condition or at risk of said disease or condition, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt.

In addition, a method for treating or reducing the risk of neuroinflammatory disorders, cardiovascular atherosclerotic disorders and atherosclerotic disorders of cerebral vessels or peripheral arterial disease, or respiratory diseases such as chronic obstructive pulmonary disease in a subject suffering from said disease or condition or at risk is also provided. said disease or condition, comprising administering to a subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

In addition, a method for treating or reducing the risk of multiple sclerosis in a subject suffering from said disease or condition or at risk of said disease or condition is provided, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

Also provided is a method of treating or reducing the risk of atherosclerosis by preventing and / or reducing the formation of new atherosclerotic lesions or plaques and / or by preventing or slowing the development of existing lesions and plaques in a subject suffering from said disease or condition or at risk of said disease or condition, comprising administering subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

Also provided is a method of treating or reducing the risk of atherosclerosis by changing the composition of the plaques so as to reduce the risk of plaque separation and atherothrombotic complications in a subject suffering from said disease or condition or at risk of said disease or condition, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or its pharmaceutically acceptable salt.

In another aspect of the present invention, there is provided a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof in a mixture with a pharmaceutically acceptable adjuvant, diluent or carrier for use in the treatment or prevention of diseases or conditions in which inhibition of the MPO enzyme is useful .

In another aspect of the present invention, there is provided a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof in a mixture with a pharmaceutically acceptable adjuvant, diluent or carrier for use in the treatment or prevention of neuroinflammatory disorders.

In another aspect of the present invention, there is provided a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof in a mixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in the treatment or prevention of multiple sclerosis, cardiovascular atherosclerotic disorders, atherosclerotic vascular disorders brain diseases of peripheral arteries and respiratory disorders such as chronic obstructive pain Lung of the lungs.

In another aspect, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof in a mixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in the treatment or prevention of atherosclerosis by preventing or reducing the formation of new atherosclerotic lesions and / or plaques and / or by preventing or slowing down the development of existing lesions and plaques.

In another aspect, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof in a mixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in the treatment or prevention of atherosclerosis by altering the plaque composition so as to reduce the risk separation of plaques and atherosclerotic complications.

The present invention further provides a process for preparing new compounds of formula (I) or a pharmaceutically acceptable salt, tautomer, enantiomer, diastereomer or racemate thereof, comprising reacting a compound of formula (II),

where R ¹ , R ¹² and L are as defined in formula (I), and R is C _1-6 alkoxy with oxygen in direct connection with the carbonyl in formula (II) with alkoxy, as defined above, or NH ₂ ;

with C _1-6 alkoxycarbonylisothiocyanate or phenylcarbonylisothiocyanate, where the phenyl group is optionally substituted with one or more groups independently selected from C _1-6 alkyl, halogen, C _1-6 alkoxy, NO ₂ , OH, CN, C _1-6 alkylamino or NH ₂₁ ; and, where necessary, converting the resulting compound of formula (I) or another salt thereof into a pharmaceutically acceptable salt thereof; or converting the resulting compound of formula (I) into another compound of formula (I); and, when desired, converting the resulting compound of formula (I) into its optical isomer.

In this method, a compound of formula (II) and an alkoxycarbonyl isothiocyanate or phenylcarbonyl isothiocyanate are dissolved or suspended in a suitable anhydrous organic solvent, such as dichloromethane, and stirred at 0-30 degrees, for example, at ambient temperature, until the reaction is complete, usually within 5- 60 minutes, but if necessary, during the night. Preferably, the alkoxycarbonylisothiocyanate is ethoxycarbonylisothiocyanate, and the phenylcarbonylisothiocyanate is preferably benzoylisothiocyanate. After a standard treatment, the intermediate is then optionally purified before treatment with a base such as sodium ethoxide in ethanol, aqueous sodium hydroxide or ammonia in solution, ammonia in methanol to obtain the desired compound of formula (I). The cyclization is carried out at elevated temperature either in an oil bath or in a microwave reactor. See, for example, Norman et al, J. Med. Chem. 2000, 43, 4288-4312. When ammonia is used in methanol, a pressure vessel is preferably used.

Compounds of formula (II) can be prepared by reacting a compound of formula (III) wherein R ¹² is as defined in formula I, R is as defined in formula II (see, for example, Furneaux et al, J. Org. Chem. 1999, 64, 8411-8412), and it can be carried out by

a) reductive amination. In this method, a compound of formula (III) can be mixed with an aldehyde of formula (IV), where R ¹ is as defined in formula I, in the presence of a reducing agent such as sodium cyanoborohydride or sodium triacetoxyborohydride. An acid, preferably acetic acid, can be added to catalyze this reaction. The reaction can be carried out in a solvent, such as methanol, at a temperature from ambient temperature to 50 ° C, preferably at ambient temperature. After standard processing, the product is then optionally purified by flash column chromatography. See, for example, Suzuki et al, Chem. Pharm. Bull. 2002, 50, 1163-1168, or Furneaux, RH, Tyier, PC, J. Org. Chem. 1999, 64, 8411-8412.

b) alkylation. In this method, a mesylate of formula (V), where R ¹ is as defined above, can be added to a stirred solution of a compound of formula (III), potassium iodide and a base, preferably potassium carbonate. This reaction can be carried out in a solvent such as N, N-dimethylformamide, at an elevated reaction temperature, preferably at 85 ° C. The reaction mixture can be treated by extraction and then purified by flash column chromatography to give a compound of formula (II).

c) crosslinking a compound of formula (III) with a suitable aryl of compound (VI), wherein R ¹ is as defined above and Halo is halogen, preferably bromo, to give a compound of formula (II). This reaction can be carried out using a suitable palladium catalyst, such as Pd ₂ (dba) ₃ or Pd (OAc) ₂ , together with a suitable ligand, such as BINAP. In this reaction, which is carried out in a temperature range from 80 ° C. to 100 ° C., a suitable base such as cesium carbonate can be used in a suitable solvent such as tetrahydrofuran, dioxane or toluene. See, for example, JP Wolfe, SL Buchwald J. Org. Chem. 2000, 65, 1144-1157.

Compounds of formula (II) are either known in the literature or can be prepared using known methods that will be readily understood by one of ordinary skill in the art. See, for example, Suzuki et al, Chem. Pharm. Bull. 2002, 50, 1163-1168, or Furneaux, R. H., Tyier, P. C., J. Org. Chem. 1999, 64, 8411-8412.

Compounds of formulas (IV), (V) and (VI) are either commercially available or can be prepared using methods that are well known in the literature.

The present invention includes compounds of formula (I) in the form of salts. Suitable salts include salts formed with organic or inorganic acids, or with organic or inorganic bases. Such salts will usually be pharmaceutically acceptable, although salts of acids or bases that are not pharmaceutically acceptable may be useful in the preparation and purification of the subject compound. Thus, preferred acid addition salts include those formed from hydrochloric, hydrobromic, sulfuric, phosphoric, citric, tartaric, lactic, pyruvic, acetic, succinic, fumaric, maleic, methanesulfonic and benzenesulfonic acids. Preferred base addition salts include salts in which the cation is sodium, potassium, calcium, aluminum, lithium, magnesium, zinc, choline, ethanolamine or diethylamine.

Salts of the compounds of formula (I) can be prepared by reacting the compound, or a salt, enantiomer or racemate thereof with one or more than one equivalent of a suitable acid or base. This reaction can be carried out in a solvent or medium in which the salt is insoluble, or in a solvent in which the salt is soluble, for example, in water, dioxane, ethanol, tetrahydrofuran or diethyl ether, or in a mixture of solvents that can be removed in vacuo or freeze-drying. This interaction can also be an exchange process, or it can be carried out on an ion exchange resin.

The compounds of the invention and intermediates for them can be isolated from their reaction mixtures and, if necessary, further purified using standard procedures.

The compounds of formula (I) may exist in enantiomeric forms. Therefore, all enantiomers, diastereomers, racemates, tautomers and mixtures thereof are included in the scope of this invention. Different optical isomers can be isolated by resolving a racemic mixture of compounds using conventional techniques, for example, fractional crystallization or HPLC. Alternatively, various optical isomers can be obtained directly using optically active starting materials.

Intermediates may also exist in enantiomeric forms and may be used as purified enantiomers, diastereomers, racemates or mixtures.

The compounds of formula (I) may exist in tautomeric forms. All such tautomers and mixtures of tautomers are included in the scope of this invention.

Intermediates can also exist in tautomeric forms and can be used as purified tautomers or mixtures.

The compounds of formula (I) and their pharmaceutically acceptable salts are useful since they have pharmacological activity as inhibitors of the MPO enzyme.

The compounds of formula (I) and their pharmaceutically acceptable salts are indicated for use in the treatment or prevention of diseases or conditions in which modulation of the activity of the myeloperoxidase enzyme (MPO) is desired. In particular, the association of MPO activity with the disease was implied in neuroinflammatory diseases. Therefore, the compounds of the present invention are particularly indicated for use in the treatment of neuroinflammatory conditions or disorders in mammals, including humans. It is also shown that these compounds are useful in the treatment of cardiovascular atherosclerotic disorders and atherosclerotic disorders of cerebral vessels or in peripheral arterial disease. These compounds have also been shown to be useful in the treatment of respiratory disorders, such as respiratory tract disorders: obstructive airway diseases including asthma, including bronchial, allergic, endogenous, exogenous, stress asthma, drug-induced asthma (including aspirin-induced asthma and non-steroidal anti-inflammatory drug (NSAID)) and dust-induced asthma, both intermittent and persistent, and of all degrees of severity, and other ichin hyperresponsiveness of the respiratory tract;

chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis; cystic fibrosis; sarcoidosis; allergic alveolitis in agricultural workers and related diseases; hypersensitive pneumonia; pulmonary fibrosis, including cryptogenic fibrous alveolitis, ideopathic interstitial pneumonia, fibrosis complicating antineoplastic therapy, and chronic infection, including tuberculosis and aspergillosis and other fungal infections; complications of lung transplantation; vascular and thrombotic disorders of the vessels of the lung and pulmonary hypertension;

antitussive activity, including treatment of chronic cough associated with inflammatory and secretory conditions of the respiratory tract, and iatrogenic cough; acute and chronic rhinitis, including drug rhinitis and vasomotor rhinitis; year-round and seasonal allergic rhinitis, including hay fever (rhinitis nervosa); polyposis of the nose; acute viral infection, including the common cold and infections caused by the respiratory syncytial virus, influenza virus, coronavirus (including SARS) and adenovirus. Such conditions or disorders will be readily apparent to those skilled in the art.

Conditions or disorders that can be specifically mentioned include multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and stroke, as well as other inflammatory diseases or disorders such as asthma, chronic obstructive pulmonary disease, cystic fibrosis, idiopathic pulmonary fibrosis, syndrome acute respiratory failure, sinusitis, rhinitis, psoriasis, dermatitis, uveitis, gingivitis, atherosclerosis, myocardial infarction, stroke, coronary heart disease, coronary heart disease, rest ERA, inflammatory bowel disease, glomerullyarnoe kidney damage, liver fibrosis, sepsis, proctitis, rheumatoid arthritis, and inflammation associated with reperfusion injury, spinal cord injury and tissue damage / scarring / adhesion / rejection. It was also suggested that lung cancer is associated with high levels of MPO. These compounds are also expected to be useful in the treatment of pain.

Prevention is expected to be particularly appropriate for treating subjects who have suffered from a previous episode or were otherwise considered at risk for the disease or condition in question. Subjects at risk of developing a particular disease or condition typically include those who have a family history of the disease or condition, or those identified through genetic analysis or screening as being particularly at risk of developing the disease or condition.

Regarding the aforementioned therapeutic indications, the dosage administered will of course vary, depending on the compound used, the route of administration and the treatment desired. However, in general, satisfactory results are obtained when the compounds are administered in a solid dosage form of from 1 mg to 2000 mg per day.

The compounds of formulas (I) and their pharmaceutically acceptable salts can be used alone or in the form of suitable pharmaceutical compositions in which the compound or derivative is mixed with a pharmaceutically acceptable adjuvant, diluent or carrier. Thus, another aspect of the present invention relates to a pharmaceutical composition comprising a new compound of formula (I) or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier. Administration may be by enteral (including oral, sublingual or rectal), intranasal route, inhalation, intravenous, local or other parenteral routes, but is not limited to them. Conventional techniques for selecting and preparing suitable pharmaceutical compositions are described, for example, in Pharmaceuticals - The Science of Dosage Form Designs, M.E. Aulton, Churchill Livingstone, 1988. The pharmaceutical composition preferably contains less than 80% and more preferably less than 50% of the compound of formula (I) or a pharmaceutically acceptable salt thereof.

Also proposed is a method of obtaining such a pharmaceutical composition, comprising mixing the ingredients.

Pharmaceutical Composition Examples

The following illustrates representative pharmaceutical dosage forms containing a compound of formula I, or its salts, solvates or solvated salts (indicated below as compound X) for prophylactic or therapeutic use in mammals:

(a): Tablet m g / tablet Compound X one hundred Lactose 182.75 Croscarmellose sodium 12.0 Corn Starch Paste (5% w / v paste) 2.25 Magnesium stearate 3.0 (b): Capsule m g / capsule Compound X 10 Lactose 488.5 Magnesium stearate 1,5 (c): Injection (50 mg / ml) Compound X 5.0% w / v 1 M sodium hydroxide solution 15.0% v / v 0.1 M hydrochloric acid (to bring to pH 7.6) Polyethylene glycol 400 4.5% w / v Water for injection up to 100%

The above compositions can be obtained by traditional methods well known in the pharmaceutical field.

This invention further relates to combination therapies, wherein a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition or preparation containing a compound of formula (I) is administered simultaneously or sequentially with a therapy and / or with an agent for treating any of the cardio vascular atherosclerotic disorders or atherosclerotic disorders of cerebral vessels and peripheral artery disease.

In particular, a compound of formula (I) or a pharmaceutically acceptable salt thereof may be administered in combination with compounds from one or more of one of the following groups:

1) anti-inflammatory agents, for example

a) NSAIDs (e.g. acetylsalicylic acid, ibuprofen, naproxen, flurbiprofen, diclofenac, indomethacin);

b) leukotriene synthesis inhibitors (5-LO inhibitors, for example, AZD4407, zileuton, lycophelon, CJ13610, CJ13454; FLAP inhibitors, for example, BAY-Y-1015, DG-031, MK591, MK886, A81834; LTA4 hydrolase inhibitors, for example SC56938, SC57461A);

c) antagonists of the leukotriene receptor (for example, CP195543, amelubant, LY293111, accolate, MK571);

2) antihypertensive agents, for example

a) beta-blockers (e.g. metoprolol, atenolol, sotalol);

b) angiotensin-converting enzyme inhibitors (e.g. captopril, ramipril, quinapril, enalapril);

c) calcium channel blockers (e.g. verapamil, diltiazem, felodipine, amlodipine);

d) angiotensia II receptor antagonists (e.g., irbesartan, candesartan, telemisartan, losartan);

3) anticoagulants, for example,

a) thrombin inhibitors (e.g. ximelagatran), heparins,

factor Xa inhibitors;

b) platelet aggregation inhibitors (for example, clopidrogrel, ticlopidine, prasugel, AZ4160);

4) lipid metabolism modulators, for example,

a) insulin sensitizers, such as peroxisome proliferator-activated receptor agonists (PPARs) (e.g. pioglitazone, rosiglitazone, halide, muraglitazaar, hefemrosil, fenofibrate);

b) inhibitors of HMG-CoA reductase, statins (for example, simvastatin, pravastatin, atorvastatin, rosuvastatin, fluvastatin);

c) cholesterol absorption inhibitors (e.g. ezetimibe);

d) IBAT inhibitors (e.g., AZD-7806);

d) LXR agonists (e.g. GW-683965A, T-0901317);

e) FXR receptor modulators;

g) phospholipase inhibitors;

5) anti-angina agents, for example nitrates and nitrites;

6) oxidative stress modulators, for example antioxidants (probucol).

General methods

All solvents used were of analytical quality, and commercially available anhydrous solvents were commonly used for the reactions. The reactions were usually carried out in an inert atmosphere of nitrogen or argon.

¹ H and ¹³ C NMR spectra were recorded at 400 MHz for proton and at 100 MHz for carbon-13 either on a Varian Unity + NMR spectrometer equipped with a 5 mm BBO measuring head with Z gradients or on a Bruker Avance 400 NMR spectrometer equipped 60 μl double inverted current measuring head with Z-gradients, or on a Bruker DPX400 NMR spectrometer equipped with a 4-core measuring head equipped with Z-gradients. Unless specifically noted in the examples, spectra were recorded at 400 MHz for proton and at 100 MHz for carbon-13. The following reference signals were used: the middle line of DMSO-d ₆ δ 2.50 ( ¹ N), 5 39.51 ( ¹³ C); the middle line of CD ₃ OD δ 3.31 ¹ N) or 5 49.15 ( ¹³ C); acetone-d ₆ 2.04 ¹ H), 206.5 ( ¹³ C); and CDCl ₃ δ 7.26 ( ¹ H), midline CDCl ₃ 5 77.16 ( ¹³ C) (unless otherwise indicated).

Mass spectra were recorded on a Waters LCMS consisting of Alliance 2795 (LC), Waters PDA 2996, an ELS detector (Sedex 75) and a single quadrupole ZMD mass spectrometer. This mass spectrometer was equipped with an electrospray ion source (ER) operating in the positive or negative ion mode. The capillary voltage was 3 kV, and the cone voltage was 30 V. This mass spectrometer scanned in the range of t / g 100-600 with a scan time of 0.7 s. The column temperature was set to 40 ° C. A diode array detector scanned in the range of 200 to 400 nm. The temperature of the ELS detector was adjusted to 40 ° C, and the pressure was set at 1.9 bar (190 kPa). A linear gradient was used to separate LCs, starting from 100% A (A: 10 mM NhitOAc in 5% MeCN) and ending at 100% B (B: MeCN) after four minutes. The column used was X-Terra MS C8, 3.0 × 50; 3.5 μm (Waters) operating at a speed of 1.0 ml / min.

Alternatively, mass spectra were acquired on GC-MS (GC 6890, 5973N MSD) equipped with Agilent Technologies. The column used was VF-5 MS, ext. diameter 0.25 mm × 30 m, 0.25 μm (Varian Inc.). A linear temperature gradient was used, starting at 40 ° C (held for 1 min) and ending at 300 ° C (held for 1 min), 25 ° C / minute. The MS was equipped with a CI ion source, and the reagent gas was methane. MS was scanned in the range of m / z 50-500, and the scanning speed was set to 3.25 scans / s. MS was equipped with an ion source EI. MS was scanned in the range of m / z 50-500, and the scanning speed was set to 3.25 scans / s. The electron voltage was set at 70 eV.

HPLC (high performance liquid chromatography) analyzes were performed on an Agilent HP1100 system consisting of a G1379A micro-vacuum degasser, a G1312A binary pump, a G1367A Well autosampler, a G1316A thermostatic column cell, and a G1315B diode array detector. Column: X-Terra MS, Waters, 3.0 × 100 mm, 3.5 μm. The column temperature was set at 40 ° C and the flow rate at 1.0 ml / min. A diode array detector scanned in the range of 210-300 nm, the step and peak width were set to 2 nm and 0.05 min, respectively.

A linear gradient was used, starting from 100% A (A: 10 mM NH40Ac in 5% MeCM) and ending at 100% B (B: MeCM) in 6 minutes.

Microwave heating was carried out in the initiator or in the Smith synthesizer with a single-mode microwave capacity, giving continuous radiation with a frequency of 2450 MHz.

A typical post-reaction treatment procedure was to extract the product with a solvent such as ethyl acetate, rinse with water, then dry the organic phase over MgSO ₄ or Na ₂ SO ₄ , filter and concentrate the solution in vacuo.

Thin layer chromatography (TLC) was performed on Merck TLC plates (silica gel 60 F ₂₅₄ ) and spots were visualized at UV. Flash column chromatography was performed on a Combi Flash® Companion ™ using a RediSep ™ normal phase flash column. Typical flash column chromatography solvents used were chloroform / methanol, dichloromethane / methanol and heptane / ethyl acetate mixtures.

Preparative chromatography was performed on a Waters auto-HPLC with a diode array detector. Column: XTegg MS C8, 19 × 300 mm, 10 μm. Narrow gradients with MeCM / (95: 5 0.1 M NH ₄ OAc: MeCN) were used at a flow rate of 20 ml / min. Alternatively, another column was used; Atlantis C18 19 × 100 mm, 5 μm column. A gradient with acetonitrile / 0.1 M ammonium acetate in 5% acetonitrile in MilliQ water was run from 0% to 35-50% acetonitrile in 15 minutes. Flow rate: 15 ml / min. Alternatively, purifications were achieved on a Shimadzu LC-8A semi-preparative HPLC unit with a Shimadzu UV-Vis detector SPD-10A equipped with a Waters Symmetry® column (C18, 5 μm, 100 mm × 19 mm). Narrow gradients with MeCM / 0.1% trifluoroacetic acid in MilliQ water were used at a flow rate of 10 ml / min.

Recrystallization was usually carried out in solvents or solvent mixtures such as ether, ethyl acetate / heptane and methanol / water.

The following abbreviations were used: aq. water; Binap 2,2'bis (diphenylphosphino) -1,1'binaphthyl eq. equivalent; DMF N, N-dimethylformamide; Dmso dimethyl sulfoxide; DIBAL diisobutylaluminum hydride; Et ₃ N triethylamine; SPLAc acetic acid; NaBH ₄ sodium borohydride; NaCNBH ₃ sodium cyanoborohydride; Pd ₂ (dba) ₃ tris (dibenzylideneacetone) dipalladium; Pd (OAc) ₂ palladium diacetate; room temp. room temperature; TBDMSCI tert-butyldimethylsilyl chloride; TEMPO 2,2,6,6-tetramethyl-1-piperidinyloxy; Thf tetrahydrofuran.

The starting materials used were either available from commercial sources or obtained according to literature methods and had experimental data corresponding to literature data. The following is an example of the starting material that was obtained: 3-amino-1H-pyrrole-2-carboxylic acid ester: Furneaux, R.H., Tyier, P.O., J. Org. Chem. 1999, 64, 8411-8412.

General method A

The reaction mixture of aminopyrrole ether A1 (1.0 eq.), Aldehyde A2 (1.0 to 2.0 eq.) And NaCNBH ₃ (1.0 eq.) In methanol was stirred at room temperature. pace. within 24 hours. In some examples, acetic acid (1 to 2 equivalents) was added in order to catalyze this reaction. If the reaction did not end after 24 hours (monitored by TLC or LC-MS), an additional amount of aldehyde A2 was added and the mixture was stirred at room temperature. pace. until the reaction to complete. This mixture was then evaporated on silica gel and purified by flash column chromatography.

General method B

Ethoxycarbonyl isothiocyanate B2 (1.0 to 1.2 equiv.) Was added to the aminopyrrole ether B1 (1.0 equiv.) In CH ₂ Cl ₂ and the mixture was stirred at room temperature. pace. for 5-60 minutes or overnight. Water was added and the aqueous phase was extracted with CH ₂ Cl ₂ . The organic phase was combined, dried (MgSO ₄ ) and concentrated. The crude open ring intermediate was purified by flash column chromatography. The intermediate was dissolved in 1 M NaOEt in EtOH (1.1-1.5 equiv.) And heated in a microwave reactor for 10 minutes at 120 ° C. The pH was adjusted to a neutral pH of 2 M HCl; the solid was collected by filtration and washed with water. The crude product was purified using preparative HPLC either by flash column chromatography or by recrystallization.

The invention is illustrated, but in no way limited by the following examples. Except where otherwise indicated, the compounds of Examples 1a to 4a and 5c and 7b were obtained using the methodology of General Method A, and the compounds of Examples 1b to 4b and 5g and 7b were obtained using the methodology of General Method B.

Example 1

1-Butyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) 3- (Butylamino) -1H-pyrrole-2-carboxylic acid ethyl ester The title compound was obtained as an oil in a 60% yield, starting from 3-amino-1H-pyrrole-2- ethyl ester carboxylic acid (0.81 g, 5.26 mmol) and butyraldehyde (0.47 + 0.55 ml, 11.4 mmol).

¹ H NMR (DMSO-d ₆₎ δ mn ^-1 10.71 (1H, br s), 6.74 (1H , t, J = 3.1 Hz), 5.62 (1H, t, J = 2.6 Hz) 5.19 (1H, s) , 4.17 (2H, q, J = 7.0 Hz), 3.04 (2H, q, J = 6.6 Hz), 1.50 (2H, m), 1.34 (2H, m), 1.25 (3H, t, J = 7.0 Hz) 0.90 (3H, t, J = 7.3 Hz);

MC (ERI) (electrospray ionization mass spectroscopy) m / z 211 (M + 1).

(b) 1-Butyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

The title compound was obtained as a solid in 44% yield, starting from 3- (butylamino) -1H-pyrrol-2-carboxylic acid ethyl ester (0.10 g, 0.48 mmol) and ethoxycarbonylisothiocyanate ( 0.06 ml, 0.58 mmol).

¹ H NMR (DMSO-d ₆₎ δ mn ^-1 12.38 (1H, s), 12.10 (1H, s), 7.37 (1H, d, J = 2.9), 6.31 ( 1H, d, J = 2.6 Hz); 4.36 (2H, m), 1.69 (2H, m), 1.38 (2H, m), 0.92 (3H, t, J = 7.5 Hz);

MS (ERI) m / z 224 (M + 1).

Example 2

1-Isobutyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) 3- (Isobutylamino) -1H-pyrrole-2-carboxylic acid ethyl ester

The title compound was obtained as an oil in 71% yield starting from 3-amino-1H-pyrrole-2-carboxylic acid ethyl ester (0.40 g, 2.59 mmol) and isobutyraldehyde (0.26 +0.07 ml, 3.61 mmol).

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 10.68 (1H, s), 6.74 (1H, t, J = 3.0 Hz), 5.62 (1H. T, J = 2.4 Hz), 5.30 (1H, brs) , 4.18 (2H, q, J = 7.2 Hz), 2.88 (2H, t, J = 6.4 Hz), 1.79 (1H, m), 1.26 (3H, t, J = 7.1 Hz), 0.90 (3H, s) 0.89 (3H, s);

¹³ C NMR (DMSO-d ₆ ) δ ppm ^-1 160.9, 124.2, 95.0, 58.2, 52.4, 27.9, 20.0, 14.7;

MS (ERI) m / z 211 (M + 1).

(b) 1-Isobutyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

The title compound was obtained as a solid in 24% yield starting from 3- (isobutylamino) -1H-pyrrole-2-carboxylic acid ethyl ester (0.38 g, 1.79 mmol) and ethoxycarbonylisothiocyanate ( 0.24 ml, 2.15 mmol).

¹ H NMR (DMSO-d ₆₎ δ mn ^-1 12.36 (1H, br s), 12.13 (1H, br s), 7.35 (1H, d, J = 2.8 Hz), 6.34 (1H, d, J = 2.8 Hz), 4.21 (2H, d, = 7.33 Hz), 2.44 (1H, m), 0.91 (3H, s), 0.90 (3H, s);

¹³ C NMR (DMSO-de) 5 ppm ^-1 172.8, 152.4, 137.3, 127.7, 113.6, 97.1, 56.2, 26.4, 19.7;

MS (ERI) m / z 224 (M + 1).

Example 3

1- (Pyridin-2-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) 3 - [(Pyridin-2-ylmethyl) amino] -1H-pyrrole-2-carboxylic acid ethyl ester

The title compound was obtained as an oil in 54% yield starting from 3-amino-1H-pyrrole-2-carboxylic acid ethyl ester (0.40 g, 2.59 mmol) and 2-pyridinecarboxaldehyde (0 , 27 + 0.07 ml, 3.55 mmol).

¹ H NMR (DMSO-d ₆₎ δ mn ^-1 10.77 (1H, br s), 8.52 (1H , d, J = 4.0 Hz), 7.80-7.67 (1H, m) , 7.35 (1H, d, J = 7.8 Hz), 7.25 (1H, dd, J = 7.3, 5.0 Hz), 6.71 (1H, t, J = 3.0 Hz), 6.10 (1H, br s), 5.57 (1H, t, J = 2.4 Hz), 4.37 (2H, d, J = 5.8 Hz), 4.21 (2H, q, J = 7.2 Hz), 1.29 (3H, t, J = 7.1 Hz);

MS (ERI) m / z 246 (M + 1).

(b) 1- (Pyridin-2-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

The title compound was obtained as a solid in 14% yield starting from 3 - [(pyridin-2-ylmethyl) amino] -1H-pyrrole-2-carboxylic acid ethyl ester (0.34 g, 1 , 39 mmol) and ethoxycarbonyl isothiocyanate (0.19 ml, 1.66 mmol).

¹ H NMR (DMSO-d ₆₎ δ mn ^{-1 12.34 (2H, br s)} , 8.49 (1H, d, J = 4.5 Hz), 7.73 (1H, m) , 7.29 (1H, d, J = 2.8 Hz ), 7.27 (1H, m), 7.21 (1H, d, J = 7.8 Hz), 6.09 (1H, d, J = 2.8 Hz), 5.75 (2H, s);

¹³ C NMR (DMSO-d ₆ ) δ ppm ^-1 173.4, 155.2, 152.6, 149.1, 137.1, 136.8, 127.9, 122.4, 121.2, 113.6.96.9.54.2;

MC (ERI) m / z 259 (M + 1).

Example 4

1- (2-Fluoro-benzyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) 3- (2-Fluoro-benzylamino) -1H-pyrrole-2-carboxylic acid ethyl ester

The title compound was obtained as an oil in quantitative yield starting from 3-amino-1H-pyrrole-2-carboxylic acid ethyl ester (0.50 g, 3.2 mmol) and 2-fluorobenzaldehyde (0.34 ml) , 3.2 mmol) using general procedure A, but with the following modifications. After 5 hours, an additional amount of NaCNBH ₃ (100 mg, 1.6 mmol) was added, followed by an additional amount of 2-fluorobenzaldehyde (120 mg, 1 mmol), and then the reaction mixture was stirred overnight.

¹ H NMR (DMSO-d ₆₎ δ mn ^-1 10.76 (1H, br s), 7.47 (1H, m), 7.38 (1H, m), 7.28 (2H, m), 6.70 ( 1H, m), 5.74 (1H, br s), 5.61 (1H, m), 4.34 (2H, m), 4.18 (2H, q, J = 7.1 Hz), 1.25 (3H, t, J = 7.1 Hz);

MS (ERI) m / z 263 (M + 1).

(b) 1- (2-Fluoro-benzyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

The title compound was obtained as a solid in 45% yield, starting from 3- (2-fluorobenzylamino] -1H-pyrrole-2-carboxylic acid ethyl ester (0.85 g, 3.2 mmol) and ethoxycarbonyl isothiocyanate (0.44 ml, 3.9 mmol).

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 12.41 (2H, br s.), 7.33 (2H, m), 7.24 (1H, m), 7.10 (1H, m, J = 7.5, 7.5 Hz), 7.01 (1H, m, J = 7.1 Hz, 7.1 Hz), 6.12 (1H, d, J = 2.8 Hz), 5.72 (2H, s);

¹³ C NMR (DMSO-d ₆ ) δ ppm ^-1 173.9, 161.4, 159.0, 152.9, 137.1, 129.6, 129.5, 128.5, 128.1, 128.1, 125.0, 124.9, 123.2, 123.0, 115.8, 115.6, 114.1, 96.9, 47.1 , 47.1;

MS (ERI) m / z 276 (M + 1).

Example 5

1- [2- (2-Methoxyethoxy) -3-propoxybenzyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) 3-Hydroxy-2- (2-methoxyethoxy) benzaldehyde

2-Chloroethyl methyl ether (4.63 ml, 50.7 mmol) was added dropwise to a mixture of 2,3-dihydroxybenzaldehyde (7.0 g, 50.7 mmol), potassium iodide (8.41 g, 50.69 mmol) and potassium carbonate (7.71 g, 55.8 mmol) in DMF (80 ml). The resulting mixture was stirred at room. temp. in a nitrogen atmosphere for two days and at 70 ° C for two days. The reaction mixture was partitioned between saturated ammonium chloride (aq.) And CH ₂ Cl ₂ . The aqueous phase was re-extracted with CH ₂ Cl ₂ , and the combined organic phases were washed with brine, dried (Na ₂ SO ₄ ) and evaporated on silica.

Purification by flash column chromatography (heptane / ethyl acetate gradient; 0 to 30% ethyl acetate) gave a crude oil, which was further purified by flash column chromatography (heptane / ethyl acetate gradient; 0 to 40% ethyl acetate) to give the title compound ( 3.13 g, 31%) as an oil.

¹ H NMR (DMSO-d ₆₎ δ mn ^-1 10.34 (1H, br s), 9.88 (1H , br s), 7.16 (2H, m), 7.05 (1H, m), 4.25 (2H, m), 3.60 (2H, m); 3.26 (3H, m);

¹³ C NMR (DMSO-d ₆ ) δ ppm ^-1 190.5, 150.7, 149.6, 129.9, 124.1, 122.6, 116.9, 72.1,70.9,57.9;

MC (ERI) m / z 197 (M + 1).

(b) 2- (2-Methoxyethoxy) -3-propoxybenzaldehyde

1-Iodopropane (3.09 ml, 31.60 mmol) was added to a solution of 3-hydroxy-2- (2-methoxyethoxy) benzaldehyde (3.1 g, 15.8 mmol) and potassium carbonate (4.37 g, 31 , 60 mmol) in DMF (80 ml) and the mixture was stirred at 100 ° C. overnight under nitrogen. The reaction mixture was partitioned between saturated ammonium chloride (aq.) And CH ₂ Cl ₂ . The organic phase was washed with brine, dried (Na ₂ SO ₄ ) and concentrated to give the title compound in quantitative yield (3.8 g) as an oil. This material was used in the next step without further purification.

¹ H NMR (DMSO-d ₆₎ δ mn ^{-1 10.37 (1H, s),} 7.36 (1H, m, J = 8.0 Hz), 7.26 (1H, m) , 7.17 (1H. T, J = 7.8 Hz) , 4.28 (2H, m), 4.02 (2H, t, J = 6.3 Hz), 3.62 (2H, m), 3.26 (3H, s), 1.80 (2H, m), 1.02 (3H, t, J = 7.3 Hz);

¹³ C NMR (DMSO-d ₆ ) δ ppm ^-1 190.3, 152.1, 150.9, 129.6, 124.4, 119.4, 117.8, 72.5, 70.9, 70.0, 57.9, 22.1, 10.4;

MS (3PH) m / z 239 (M + 1).

(c) 3 - {[2- (2-Methoxyethoxy) -3-propoxybenzyl] amino} -1H-pyrrole-2-carboxylic acid ethyl ester

The title compound was obtained as an oil in quantitative yield starting from 3-amino-1H-pyrrole-2-carboxylic acid ethyl ester (0.35 g, 2.27 mmol) and 2- (2-methoxyethoxy) - 3-propoxybenzaldehyde (0.47 + 0.08 g, 3.06 mmol).

¹ H NMR (DMSO-d ₆₎ 5 million ^-1 10.69 (1H, brs), 7.13 (1H, s), 7.6.99 (2H, m), 6.70 (1H, m), 5.63 (1H, m), 4.92 (1H, t, J = 5.7 Hz), 4.52 (2H, d, J = 5.8 Hz), 4.19 (2H, m), 4.05 (2H, m), 3.92 (2H, t, J = 6.4 Hz), 3.59 (2H, m), 3.32 (3H, s), 1.76 (2H, m), 1.26 (3H, t, J = 7.1 Hz), 1.00 (3H, m);

MS (ERI) m / z 377 (M + 1).

(g) 1- [2- (2-Methoxyethoxy) -3-propoxybenzyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

The title compound was obtained as a solid in 13% yield starting from 3 - {[2- (2-methoxyethoxy) -3-propoxybenzyl] amino} -1H-pyrrole-2-carboxylic acid ethyl ester ( 0.87 g, 2.31 mmol) and ethoxycarbonyl isothiocyanate (0.26 ml, 2.31 mmol).

¹ H NMR (DMSO-d ₆₎ δ mn ^{-1 12.43 (1H, br s)} , 12.31 (1H, br s), 7.29 (1H, d, J = 3.0 Hz), 6.96-6.85 (2H, m) , 6.41 (1H, dd, J = 7.3, 1.5 Hz), 6.02 (1H, d, J = 2.8 Hz), 5.71 (2H, s), 4.23 (2H, m), 3.95 (2H, t, J = 6.3 Hz ), 3.65 (2H, m), 3.33 (3H, s), 1.82-1.72 (2H, m), 1.02 (3H, t, J = 7.4 Hz);

MC (ERI) m / z 390 (M + 1).

Example 6

1- (6-Ethoxy-pyridin-2-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) 6-Ethoxy-pyridin-2-carboxylic acid ethyl ester Ethyl iodide (2.3 ml, 28.8 mmol) was added to a suspension of 6-hydroxy-pyridin-2-carboxylic acid (1.0 g, 7.2 mmol) and silver carbonate (1) (4.0 g, 14.4 mmol) in CHCl ₃ (70 ml). This suspension was stirred at ambient temperature for 3 days. Insoluble matter was removed by filtration and the solid was washed with CHCl ₃ . The filtrate was concentrated to give the title product in quantitative yield (1.5 g) as an oil. This material was used in the next step without further purification.

¹ H NMR (CDCl ₃₎ δ mn ^{-1 7.65 (2H, m),} 6.88 (1H, m), 4.45 (2H, q, J = 7.0 Hz), 4.41 (2H, q, J = 7.3 Hz), 1.40 (6H, m);

MC (ERI) m / z 196 (M + 1).

(b) (6-Ethoxy-pyridin-2-yl) -methanol

NaBH ₄ (5.7 g, 151 mmol) was added portionwise to 6-ethoxy-pyridin-2-carboxylic acid ethyl ester (1.5 g, 7.5 mmol) in EtOH (75 ml) over 35 minutes. The resulting mixture was stirred at ambient temperature for two days. Water was added and the mixture was extracted with CH ₂ Cl ₂ . The organic phase was dried (Na ₂ SO ₄ ), filtered and then concentrated to give the title compound (0.85 g) in 74% yield as an oil. This material was used in the next step without further purification.

¹ H NMR (CDCl ₂ ) δ ppm ^-1 7.55 (1H, m), 6.77 (1H, d, J = 7.4 Hz), 6.61 (1H, d, J = 8.1 Hz), 4.66 (2H, d, J = 5.3 Hz), 4.38 (2H, q, J = 7.1 Hz), 3.46 (1H, t, J = 5.2 Hz), 1.41 (3H, t, J = 7.1 Hz).

(c) 6-Ethoxy-pyridin-2-carbaldehyde

DMSO (0.50 ml, 6.4 mmol) in CH ₂ Cl ₂ (10 ml) was added dropwise to a solution of oxalyl chloride (2M in CH ₂ Cl ₂ , 3.1 ml, 6.1 mmol) in CH ₂ Cl ₂ (20 ml) at -60 ° C. The resulting mixture was stirred at -60 ° C for 10 minutes. (6-Ethoxy-pyridin-2-yl) -methanol (0.85 g, 5.6 mmol) in CH ₂ Cl ₂ (5 ml) and DMSO (4 ml) were added dropwise. This mixture was stirred at −60 ° C. for 3 hours, then allowed to warm to −20 ° C. and Et ₃ N (6 ml) was added. The resulting solution was stirred at ambient temperature for 40 minutes. Water was added and the mixture was extracted with CH ₂ Cl ₂ . The organic phase was washed with brine, dried (Na ₂ SO ₄ ) and concentrated. Diethyl ether was added to the residue and insoluble substances® were removed by filtration. The filtrate was concentrated to give the title compound (0.60 g) in 70% yield as a solid. This crude product was used in the next step without further purification.

¹ H NMR (CDCl ₂₎ δ mn ^-1 9.93 (1H, s), 7.71 (1H, m), 7.53 (1H, d, J = 7.1 Hz), 6.94 (1H, d, J = 8.3 Hz), 4.46 (2H, d, J = 7.1 Hz), 1.42 (3H, t, J = 7.1 Hz).

(d) 3 - [(6-Ethoxy-pyridin-2-ylmethyl) amino] -1H-pyrrole-2-carboxylic acid ethyl ester

Acetic acid (0.3 ml) was added to 6-ethoxy-pyridin-2-carbaldehyde (0.59 g, 3.9 mmol) and 3-amino-1H-pyrrole-2-carboxylic acid ethyl ester (0.30 g 1.9 mmol) in ethanol (10 ml). After 1.5 hours, NaCNBH ₃ (0.24 g, 3.9 mmol) was added and the resulting mixture was stirred at ambient temperature for 19 hours. The solvent was removed in vacuo, ethyl acetate was added to the residue, and the insoluble matter was removed by filtration. The filtrate was concentrated and the crude product was purified by flash column chromatography (heptane / ethyl acetate gradient; 0 to 35% ethyl acetate) to give 0.25 g (45%) of the title compound as a solid.

¹ H NMR (CDCl ₂₎ δ mn ^-1 8.16 (1H, br s), 7.50 (1H , m), 6.89 (1H, d, J = 7.3 Hz), 6.70 (1H, brs) , 6.57 (1H, d , J = 8.1 Hz), 4.45 (2H, q, J = 7.0 Hz), 5.71 (1H, m), 4.38 (5H, m), 1.37 (6H, m);

MC (ERI) m / z 290 (M + 1).

(e) 1- (6-Ethoxy-pyridin-2-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

Ethoxycarbonyl isothiocyanate (0.12 g, 0.90 mmol) was added to 3 - [(6-ethoxy-pyridin-2-ylmethyl) amino] -1H-pyrrol-2-carboxylic acid ethyl ester (0.24 g, 0, 82 mmol) in CH ₂ Cl ₂ (5 ml), and this solution was stirred at ambient temperature for 35 minutes. The solvent was evaporated, 0.4 M NaOEt in ethanol (3 ml, 1.2 mmol) was added to the residue, and the mixture was refluxed for 1 h. Additional NaOEt (0.4 M in ethanol, 1.5 ml) was added. 0.6 mmol) and the solution was refluxed for another 1.5 hours. The solvent was evaporated, the residue was dissolved in water, and the pH was adjusted to a neutral pH of 1 M HCl. The resulting solid was collected, washed and dried to obtain a crude product. This material was purified by preparative HPLC to give the title compound (38 mg, 15%) as a solid.

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 12.32 (2H, br s), 7.62 (1H, m), 7.29 (1H, d, J = 3.0 Hz), 6.78 (1H, d, J = 7.3 Hz ), 6.64 (1H, d, J = 8.3 Hz), 6.13 (1H, d, J = 2.8 Hz), 5.65 (2H, s), 4.17 (2H, q, J = 7.1 Hz), 1.19 (3H, 7 , J = 7.0 Hz);

¹³ C NMR (DMSO-d ₆ ) δ ppm ^-1 173.5, 162.7, 152.8, 152.5, 139.6, 137.2, 127.8, 113.9, 113.6, 109.0.97.0.61.0.53.8, 14.3;

MS (ERI) m / z 303 (M + 1).

Example 7 1-Piperidin-3-ylmethyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) 3-Formyl-piperidine-1-carboxylic acid tert-butyl ester DMSO (0.18 ml, 2.6 mmol) in CH ₂ Cl ₂ (5 ml) was added dropwise to a solution of oxalyl chloride (2 M in CH ₂ Cl ₂ , 0.65 ml, 1.3 mmol) in CH ₂ Cl ₂ (4 ml) at -78 ° C. The resulting mixture was stirred at -68 ° C for 15 minutes. 3-Hydroxymethyl-piperidine-1-carboxylic acid mpem-butyl ester (Dean A. Wacker et al. Bioorganic & Medicinal Chemistry Letters 2002, 12, 1785-1789) (0.22 g, 1.0 mmol) was added dropwise CH ₂ Cl ₂ (4 ml), and after 15 min stirring at -78 ° C, Et ₃ N (6 ml) was added. The resulting solution was stirred at ambient temperature for 16 hours. Water was added, the mixture was extracted with diethyl ether, the organic layer was dried (Na ₂ SO ₄ ) and concentrated to give the product as a yellow oil (0.20 g, 92% yield) . This crude product was used in the next step without further purification. MS (ERI) m / z 214 (M + 1).

(b) 3 - [(2-Ethoxycarbonyl-1H-pyrrol-3-ylamino) methyl] piperidine-1-carboxylic acid tert-butyl ester

The title compound was obtained as an oil in 30% yield starting from 3-amino-1H-pyrrole-2-carboxylic acid ethyl ester (0.14 g, 0.92 mmol) and tert-butyl ether 3 Formyl piperidine-1-carboxylic acid (0.20 g, 0.92 mmol).

¹ H NMR (CDCl ₃₎ δ 8.29 mn ^-1 (1H, br s), 6.70 (1H, s), 5.67 (1H, m), 4.27 (2H, m), 3.93 ( 1H, br s), 3.85 ( 1H, d, J = 13.2 Hz), 3.10-2.94 (2H, m), 2.83 (1H, m), 2.65 (1H, br s), 1.85 (1H, m), 1.76 (1H, m), 1.64 ( 1H, m), 1.42 (9H, s), 1.31 (3H, t, J = 6.8 Hz), 1.22 (1H, m);

MC (ERI) m / z 352 (M + 1).

(c) 1-piperidin-3-ylmethyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

The title compound was obtained as a solid in 20% yield using 3 - [(2-ethoxycarbonyl-1H-pyrrol-3-ylamino) methyl] piperidine-1-carboxylic acid tert-butyl ester ( 97 mg, 0.27 mmol) and ethoxycarbonyl isothiocyanate (36 mg, 0.27 mmol) using General Procedure B with the following modifications. After a base-mediated cyclization reaction, 6 M Hcl (0.3 ml) was added to the reaction mixture, followed by heating in a microwave reactor for 4 minutes at 100 ° C. The solvent was removed in vacuo and the remaining solid was purified by preparative HPLC using an Atlantis column. C18 19 × 100 mm, 5 μm. A gradient with acetonitrile / 0.1 M ammonium acetate in 5% acetonitrile in MilliQ water was run from 0% to 50% acetonitrile in 15 minutes. Flow rate: 15 ml / min.

¹ H NMR (Methanol-d ₄ ) δ ppm ^-1 7.23 (1H, d, J = 3.2 Hz), 6.21 (1H, d, J = 3.2 Hz), 4.46 (1H, m), 4.23 (1H, m) , 3.22 (2H, m), 2.86 (2H, m), 2.58 (1H, m), 1.83 (2H, m), 1.62 (1H, m), 1.42 (1H, m);

¹³ C NMR (Methanol-d ₄ ) δ ppm ^-1 178.8, 154.7, 139.3, 129.5, 115.3, 97.8, 53.7, 48.0, 45.2, 34.5, 27.6, 23.2;

MS (ERI) m / z 265 (M + 1).

Example 8

1-Butyl-4-thioxo-1,3,4,5-tetrahydro-2H-pyrrolo [3,2-d] pyrimidin-2-one

Ethoxycarbonyl isothiocyanate (0.13 ml, 1.1 mmol) was added to 3- (butylamino) -1H-pyrrole-2-carboxylic acid ethyl ester (0.23 g, 1.1 mmol) in toluene (5 ml) and the mixture was heated at 90 ° C for 1 h. The precipitate was filtered off and washed with hexane. The intermediate was treated with potassium hydroxide (0.55 g, 9.9 mmol) in water (9 ml) and heated under reflux for 15 hours. After cooling to ambient temperature, the pH was adjusted to 5 using 12 M HCl. The resulting precipitate was collected by filtration and washed with water. The crude product was purified using preparative HPLC to give the title compound (16 mg, 6%) as a solid.

¹ H NMR (DMSO-d ₆₎ δ 12.04 mn ^-1 (1 H, br s), 11.95 (1 H, br s), 7.40 (1 H, s), 6.23 (1 H, d, J = 2.7 Hz ), 3.84 (2 H, t, J = 7.2 Hz), 1.66-1.56 (2 H, m), 1.32 (2 H, m), 0.89 (3 H, t, J = 7.3 Hz);

MC (ERI) m / z 224 (M + 1).

Example 9

1- (2-Isopropoxyethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) 3 - [(2-Isopropoxyethyl) amino] -1H-pyrrole-2-carboxylic acid ethyl ester

Trichlorocyanuric acid (1.84 g, 7.93 mmol) was added to a solution of 2-isopropoxyethanol (0.75 g, 7.21 mmol) in CH ₂ Cl ₂ (3 ml). The reaction mixture was cooled to 0 ° C. and TEMPO (0.022 g, 0.14 mmol) was carefully added in small portions. This mixture was stirred at room. pace. for 20 minutes, then filtered through celite and washed with CH ₂ Cl ₂ . During filtration, the filtrate was kept cold, 0 ° C. To a stirred mixture of 3-amino-1H-pyrrole-2-carboxylic acid ester (0.83 g, 5.41 mmol) and HOAc (0.62 ml, 10.8 mmol) at 0 ° C in methanol (5 ml) aldehyde solution was added. This mixture was stirred for 20 minutes, then NaCNBH ₃ (0.34 g, 5.41 mmol) was added. After stirring at room pace. over 2 hours, the solution was evaporated on silica and purified by flash column chromatography (heptane / ethyl acetate gradient; 0 to 100% ethyl acetate) to give the title compound (0.75 g, 58%) as an oil.

¹ H NMR (DMSO-d ₆₎ δ mn ^-1 10.72 (1H, br s), 6.76-6.74 (1H , m), 5.66-5.65 (1H, m), 5.34 ( 1H, br s), 4.17 (2H , q, J = 7.0 Hz), 3.59-3.49 (3H, m), 3.15 (2H, q, J = 5.6 Hz), 1.26 (3H, t, J = 7.0 Hz), 1.10 (3H, s), 1.08 (3H, s);

MS (ERI) m / z 241 (M + 1).

(6) 1- (2-Isopropoxyethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

The title compound (0.17 g, 23%) was obtained according to general method B using 3 - [(2-isopropoxyethyl) amino] -1H-pyrrole-2-carboxylic acid ethyl ester (0.7 g, 2 , 91 mmol) and ethoxycarbonyl isothiocyanate (0.40 ml, 3.50 mmol).

¹ H NMR (DMSO-d ₆₎ δ mn ^{-1 12.74 (2H, brs),} 7.35 (1H, d, J = 2.8 Hz), 6.29 (1H, d, J = 3.0 Hz), 4.49 (2H, t, J = 6.3 Hz), 3.72 (2H, t, J = 6.3 Hz), 3.60-3.58 (1H, m), 1.02 (3H, s), 1.01 (3H, s);

MS (ERI) m / z 254 (M + 1).

Example 10

1 - (2-Methoxy-2-methylpropyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) 3 - [(2-Methoxy-2-methylpropyl) amino] -1H-pyrrole-2-carboxylic acid ester

The title compound was obtained as an oil in 75% yield starting from 3-amino-1H-pyrrole-2-carboxylic acid ethyl ester (0.250 g, 1.62 mmol) and 2-methoxy-2-methylpropanal (US 3652579) (0.331 g, 3.24 mmol) using General Procedure A, but with the following modifications. After 6 hours, an additional amount of 2-methoxy-2-methylpropanal (0.165 g, 1.62 mmol) was added and then the reaction mixture was stirred overnight.

¹ H NMR (DMSO-d ₆₎ δ mn ^-1 10.69 (1H, br s), 6.74 (1H, t, J = 3.0 Hz), 5.64 (1H, t, J = 2.6 Hz), 5.33 (1H, br s), 4.17 (2H, q, J = 7.1 Hz), 3.11 (3H, d, J = 5.8 Hz), 1.26 (3H, t, J = 7.1 Hz), 1.13 (6H, s);

MS (ERI) m / z 241 (M + 1).

(b) 1- (2-Methoxy-2-methylpropyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

The title compound was obtained as a solid in 3% yield starting from 3 - [(2-ethoxy-2-methylpropyl) amino] -1H-pyrrole-2-carboxylic acid ethyl ester (0.283 g, 1 , 18 mmol) and ethoxycarbonyl isothiocyanate (0.13 ml, 1.18 mmol) using the general procedure B, but with the following modifications. The reaction was carried out in a microwave reactor as a whole for 35 minutes.

¹ H NMR (DMSO-d ₆₎ δ mn ^-1 12.29 (1H, br s), 12.17 (1H, br s), 7.30 (1H, d, J = 2.76), 6.29 ( 1H, d, J = 2.76) 4.58 (2H, brs); 3.12 (3H, s); 1.21 (6H, s);

MC (ERI) m / z 254 (M + 1).

Example 11

1- (2-Ethoxy-2-methylpropyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-c] pyrimid-4-one

(a) 2-Bromo-1,1-diethoxy-2-methylpropane

This product was synthesized according to the modified procedure described in US 3652579. Water bromide (2.95 ml, 57.6 mmol) was added dropwise to isobutyraldehyde (4.82 g, 66.8 mmol) in ethanol (22 ml) and the resulting mixture stirred at room pace. for 40 minutes. Additional bromide water (0.3 ml, 5.86 mmol) was added. The reaction mixture was neutralized by the addition of calcium carbonate (3.5 g, 25.3 mmol). The remaining calcium carbonate was filtered off and the filtrate was poured onto ice-water. The aqueous phase was extracted with CH ₂ Cl ₂ , dried (Na ₂ SO ₄ ), filtered and concentrated. After vacuum distillation, the title product (10.10 g, 67%) was obtained.

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 4.43 (1H, s), 3.80-3.73 (2H, m), 1.64 (6H, s), 1.15 (6H, t, J = 7.1 Hz).

(b) 2-Ethoxy-2-methylpropanal

This product was synthesized according to the procedure described in US 3652579.

2-Ethoxy-2-methylpropanal (5.63 g, 25 mmol) was added dropwise to potassium bitartrate (2.35 g, 12.5 mmol) in deionized water boiling under reflux (22.5 ml) over the course of 50 minutes. The resulting mixture was refluxed for 70 minutes. The solvent and product were distilled off. Ammonium sulfate (total 8.5 g) was added to the product-solvent mixture. This mixture was stirred, then the two phases were separated, and the upper phase was distilled from calcium chloride to give the title product (1.60 g, 55%).

MS (CI) (chemical ionization) m / z 117 (M + 1).

(c) 3 - [(2-Ethoxy-2-methyl-propyl) amino] -1H-pyrrole-2-carboxylic acid ethyl ester

The title compound was obtained as an oil in 63% yield starting from 3-amino-1H-pyrrole-2-carboxylic acid ethyl ester (0.200 g, 1.30 mmol) and 2-ethoxy-2-methylpropionaldehyde (0.292 g, 2.86 mmol) using the general method A, but with the following modification. The reaction mixture was stirred at room. pace. within 48 hours

¹ H NMR (CDCl ₂₎ δ mn ^-1 6.74 (1H, br s), 5.70 (1H, br s), 4.32 (2H, q, J = 7.4 Hz), 3.54-3.47 (2H, m), 3.44 ( 2H, q, J = 7.6 Hz), 3.12 (2H, d, J = 4 Hz), 1.25 (6H, s), 1.20 (3H, t, J = 7.4 Hz), 1.19 (3H, t, J = 7.6 Hz);

MS (ERI) m / z 255 (M + 1).

(s) 1- (2-Ethoxy-2-methylpropyl) -2-thioxo-1,2,3,5-tetrazidro-pyrrolo [3,2-d] pyrimidin-4-one

3- (2-Methoxy-2-methyl) propylamino-1H-pyrrole-2-carboxylic acid ethyl ester (0.200 g, 0.79 mmol) was dissolved in CH ₂ Cl ₂ (2 ml) at room temperature. pace. in an atmosphere of nitrogen. Ethoxycarbonyl isothiocyanate (0.12 ml, 1.02 mmol) was added dropwise and the reaction mixture was stirred at room temperature. pace. during the night. The solvent was evaporated, sodium ethoxide (1 M in ethanol, 0.94 ml, 0.94 mmol) was added and the reaction mixture was heated to 40 ° C for 48 hours. Water (2 ml) was added and the pH adjusted to neutral using 2 M HCl. The precipitate was collected by filtration and purified by preparative HPLC to give the title compound in 6% yield (0.12 g).

¹ H NMR (DMSO-d ₆₎ δ mn ^-1 12.22 (1H, br s), 7.30 (1H, d, J = 2.8 Hz), 6.35 (1H, d, J = 3 Hz), 4.60 (2H, brs ), 3.40-3.34 (3H, m), 1.22 (6H, s), 1.04 (3H, t, J = 7.0 Hz);

MS (ERI) m / z 267 (M + 1).

Example 12

1- (piperidin-4-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) 4 - [(2- (Ethoxycarbonyl) -1H-pyrrol-3-ylamino) methyl] piperidine-1-carboxylic acid tert-butyl ester

The title compound (0.156 g, 10%) was obtained according to general method A, starting from 3-amino-1H-pyrrol-2-carboxylic acid ethyl ester (0.68 g, 4.4 mmol) and mpem-butyl 4-formylpiperidin-1-carboxylic acid ester (P. C. Ting et al., Bioorganic & Medicinal Chemistry Letters, 2001, 11, 491-494) (0.98 g, 4.6 mmol).

¹ H NMR (DMSO-d ₆₎ δ mn ^-1 10.70 (1H, br s), 6.74 (1H, br s), 5.65 (1H, br s), 4.19 (2H, q, J = 7.2 Hz), 3.95 (2H, d, J = 12.0 Hz), 2.97 (2H, t, J = 6.0 Hz), 2.65 (2H, br s), 1.66 (2H, d, J = 12.0 Hz), 1.39 (9H, s), 1.26 (3H, t, J = 7.2 Hz), 1.07-0.95 (2H, m);

MC (ERI) m / z 352 (M + 1).

(b) 1- (piperidin-4-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

Ethoxycarbonyl isothiocyanate (0.058 g, 0.44 mmol) was added to a stirred solution of 4 - [(2- (ethoxycarbonyl) -1H-pyrrol-3-ylamino) methyl] piperidine-1-carboxylic acid mpem-butyl ester (0.156 g, 0 , 44 mmol) in CH ₂ Cl ₂ (2 ml), and this mixture was stirred at room. pace. within 1 h. The solvent was removed in vacuo and the residue was dissolved in ethanol (1 ml) containing sodium (0.015 g, 0.66 mmol). The resulting mixture was heated in a microwave reactor at 120 ° C for 10 minutes. 6 M HCl (0.5 ml) was added and the reaction mixture was again heated in a microwave reactor at 100 ° C. for 3 minutes. The pH was adjusted to neutral using 2 M HCl and the solution was concentrated in vacuo. The crude product was purified by preparative HPLC to give the title compound (0.038 g, 14%) as a white solid.

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 7.36 (1H, d, J = 2.8 Hz), 6.33 (1H, d, J = 2.8 Hz), 4.27 (2H, br s), 2.95 (2H, d , J = 12.0 Hz), 2.40 (2H, t, J = 10.4 Hz), 2.25-2.15 (1H, m), 1.50 (2H, d, J = 10.8 Hz), 1.37-1.20 (2H, m);

¹³ C NMR (DMSO-d ₆ ) δ ppm ^-1 173.2, 152.9, 137.6, 128.1, 114.0, 97.5, 55.2, 45.5, 34.7, 30.0;

MC (ERI) m / z 265 (M + 1).

Example 13

1 - [(1-Methylpiperidin-3-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

1-Piperidin-3-ylmethyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one (Example 7) (0.092 g, 0.35 mmol) was dissolved in methanol (2 ml) and formic acid (37% aq., 0.059 ml, 0.7 mmol) was added. After 5 minutes of stirring at room pace. a precipitate formed. NaCNBH ₃ (0.026 g, 0.42 mmol) was added and the mixture was stirred at room temperature. pace. within 1 h. The solvent was removed in vacuo and the residual solid was purified by preparative HPLC to give the title compound (0.022 g, 22%) as a white solid.

¹ H NMR (DMSO-d ₆₎ δ mn ^-1 12.22 (1H, br s), 7.36 (1H, d, J = 2.8 Hz), 6.33 (1H, s), 4.27 (2H, br s), 2.61- 2.5 (1H, m), 2.36-2.30 (1H, m), 2.09 (3H, s), 1.93-1.82 (3H, m), 1.65-1.52 (2H, m), 1.44-1.32 (1H, m), 1.16-1.07 (1H, m);

¹³ C NMR (DMSO-d ₆ ) δ ppm ^-1 173.2, 152.9, 137.6, 128.1, 114.0, 97.3, 59.2, 56.0, 53.3, 46.7, 34.9, 27.7, 24.7;

MS (ERI) m / z 279 (M + 1).

Example 14

1- [2-Hydroxy-2- (4-methoxyphenyl) ethyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) Methyl - {[tert-butyl (dimethyl) silyl] oxy} (4-methoxyphenyl) acetate

TBDMSCI (1.5 g, 9.94 mmol) and imidazole (1.0 g, 14.6 mmol) were added to a solution of methylhydroxy- (4-methoxyphenyl) acetate (Teodozyj Kolasa et al., J. Org. Chem., 1987, 22, 4978-4984) (1.3 g, 6.62 mmol) in DMF (8 ml), and this mixture was stirred at room temperature. pace. over 2 hours. Water was added and the mixture was extracted with diethyl ether. The organic layer was washed with brine, dried (MgSO ₄ ), filtered and concentrated to give the title compound (2.0 g, 97%).

¹ H NMR (CDCl ₃ ) δ ppm ^-1 7.39 (2H, d, J = 8.8 Hz), 6.88 (2H, d, J = 8.8 Hz), 5.19 (1H, s), 3.81 (3H, s), 3.69 (3H, s), 0.92 (9H, s), 0.11 (3H, s), 0.03 (3H, s).

(b) {[tert-Butyl (dimethyl) silyl] oxy} (4-methoxyphenyl) acetaldehyde Methyl {[tert-butyl (dimethyl) silyl] oxy} (4-methoxyphenyl) acetate (0.5 g, 1.61 mmol ) was dissolved in toluene (10 ml) and cooled to -78 ° C in a nitrogen atmosphere. DIBAL (1.0 M in toluene, 1.9 ml, 1.93 mmol) was slowly added and the mixture was stirred for 1 h at -78 ° C. This reaction mixture was poured onto a mixture of ice (20 g) and CHCl ₃ (20 ml). The mixture was stirred at room. pace. within 30 minutes. The layers were separated and the aqueous phase was extracted with CHCl ₃ . The organic phase was washed with brine, dried (MgSO ₄ ), filtered and concentrated to give 99% (0.45 g) of the title compound. This product was directly used in the next step without further purification.

¹ H NMR (CDCl ₃ ) δ ppm ^-1 7.40-7.38 (2H, m), 6.89-6.87 (2H, m), 5.19 (1H, s), 3.81 (3H, s), 0.92 (9H, s), 0.11 (3H, s), 0.03 (3H, s).

(c) Ethyl 3 - {[2 - {[tert-butyl (dimethyl) silyl] oxy} -2- (4-methoxyphenyl) ethyl] amino} -1 N-pyrrole-2-carboxylic acids

The title compound (0.13 g, 19%) was obtained according to general method A using 3-amino-1H-pyrrole-2-carboxylic acid ethyl ester (0.16 g, 1.07 mmol) and {[ tert-butyl (dimethyl) silyl] oxy} (4-methoxyphenyl) acetaldehyde (0.3 g, 1.07 mmol).

MS (ERI) m / z 417 (M-1).

(d) 1- [2 - {[tert-Butyl (dimethyl) silyl] oxy} -2- (4-methoxyphenyl) ethyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2 -d] pyrimidin-4-one

The title compound (0.07 g, 90%) was obtained according to general method B using 3 - {[2 - {[mpem-butyl (dimethyl) silyl] oxy} -2- (4-methoxyphenyl) ethyl ester ethyl] amino} -1H-pyrrole-2-carboxylic acid (0.13 g, 0.31 mmol) and ethoxycarbonyl isothiocyanate (0.042 ml, 0.37 mmol).

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 12.28-12.23 (2H, m), 7.42 (2H, d, J = 8.6 Hz), 7.34-7.33 (1H, m), 6.96 (2H, d, J = 8.6 Hz), 6.33 (1H, br s), 5.53-5.50 (1H, m), 4.57 (1H, br s), 4.15 (1H, brs), 3.76 (3H, s), 0.61 (9H, s) 0.31 (3H, s); 0.39 (3H, s);

MC (ERI) m / z 432 (M + 1).

(e) 1- [2-Hydroxy-2- (4-methoxyphenyl) ethyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

Tetra-n-butylammonium fluoride (1 M in THF, 1.27 ml, 1.27 mmol) was added to 1- [2 - {[tert-butyl (dimethyl) silyl] oxy} -2- (4-methoxyphenyl) ethyl ] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one (0.065 g, 0.152 mmol) in THF (8 ml). This mixture was stirred at 50 ° C. overnight. Ethyl acetate was added, the organic phase was washed with water and brine, dried (MgSO ₄ ), filtered and concentrated. This crude material was purified by preparative HPLC to give the title compound (0.018 g, 37%) as a solid.

¹ H NMR (DMSO-d ₆₎ δ 12.20 mn ^-1 (2H, br s), 7.40 (2H, d, J = 8.5 Hz), 7.29 (1H, d, J = 2.8 Hz), 6.91 (2H, d , J = 8.8 Hz), 6.27 (1H, d, J = 2.8 Hz), 5.42-5.41 (1H, m), 5.28-5.24 (1H, m), 4.62-4.58 (1H, m), 4.19-4.16 ( 1H, m) 3.74 (3H, s);

MS (ERI) m / z 316 (M-1).

Example 15

1- (2-Methoxybenzyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) 3 - [(2-Methoxybenzyl) amino] -1H-pyrrole-2-carboxylic acid ethyl ester

The title compound was obtained as a white solid in quantitative yield starting from 3-amino-1H-pyrrole-2-carboxylic acid ethyl ester (0.350 g, 2.27 mmol) and ortho-anisaldehyde (0.37 g , 2.71 mmol) using General Procedure A, but with the following modifications. After stirring overnight, the reaction medium was evaporated. The crude solid was dissolved in CHCl ₃ , filtered and the solvent was evaporated in vacuo, this crude product was used in the next step without further purification.

MC (ERI) m / z 275 (M + 1).

(b) 1- (2-Methoxybenzyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

The title compound was obtained as a solid in 16% yield starting from 3 - [(2-methoxybenzyl) amino] -1H-pyrrole-2-carboxylic acid ethyl ester (0.622 g, 2.27 mmol) and ethoxycarbonyl isothiocyanate (0.26 ml, 2.27 mmol) using General Procedure B, but with the following modification. The intermediate crude product was dissolved in 1 M NaOEt (2.27 ml, 2.27 mmol) and stirred at 80 ° C for 3 hours.

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 12.36 (2H, br s), 7.27 (1H, d, J = 2.8 Hz), 7.27-7.21 (1H, m), 7.06 (1H, d, J = 8.1 Hz), 6.82 (1H, t, J = 7.3 Hz), 6.79-6.75 (1H, m), 5.96 (1H, d, J = 2.8 Hz), 5.61 (2H, s), 3.89 (3H, s) ;

MS (ERI) m / z 288 (M + 1).

Example 16

1- (3-Methoxybenzyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) 3 - [(3-Methoxybenzyl) amino] -1H-pyrrole-2-carboxylic acid ethyl ester

The title compound was obtained as an oil in 57% (0.508 g) yield and was prepared according to General Procedure A using 3-amino-1H-pyrrole-2-carboxylic acid ethyl ester (0.50 g, 3, 24 mmol) and m-anisaldehyde (0.47 ml, 3.89 mmol).

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 10.73 (1H, brs), 7.24-7.20 (1H, m), 6.90-6.86 (1H, m), 6.80-6.77 (1H, m), 6.71-6.69 (1Н, m), 5.75 (1Н, br s), 5.59-5.58 (1Н, m), 4.46 (1Н, d, J = 5.8 Hz), 4.25 (2Н, d, J = 6.3 Hz), 4.19 (2Н , q, J = 7.1 Hz), 3.72 (3H, s), 1.26 (3H, t, J = 7.1 Hz);

MS (ERI) m / z 275 (M + 1).

(b) 1- (3-Methoxybenzyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

The title compound was obtained as a solid in 3% (0.014 g) yield and was prepared according to general method B using 3 - [(3-methoxybenzyl) amino] -1H-pyrrole-2-carboxylic acid ethyl ester (0.494 g, 1.80 mmol) and ethoxycarbonyl isothiocyanate (0.20 ml, 1.18 mmol).

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 12.41-12.34 (2H, m), 7.29 (1H, d, J = 2.7 Hz), 7.23 (1H, t, J = 8.0 Hz), 6.93-6.91 ( 1H, t), 6.86 (1H, d, J = 7.8 Hz), 6.83 (1H, dd, J = 8.2, 2.4 Hz), 6.14 (1H, d, J = 2.8 Hz), 5.67 (2H, s), 3.71 (3H, s);

MC (ERI) m / z 288 (M + 1).

Example 17

1- (2,4-Dimethoxybenzyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) 3 - [(2,4-Dimethoxybenzyl) amino] -1H-pyrrole-2-carboxylic acid ethyl ester

The title compound was obtained as an oil in 85% (0.838 g) yield and was prepared according to General Method A using 3-amino-1H-pyrrole-2-carboxylic acid ethyl ester (0.50 g, 3, 24 mmol) and 2,4-dimethoxybenzaldehyde (0.647 g, 3.89 mmol).

¹ H NMR (DMSO-d ₆₎ δ mn ^-1 10.69 (1H, br s), 7.14 (1H, d, J = 8.3 Hz), 6.71 (1H, t, J = 3.0 Hz), 6.54 (1H, d , J = 2.3 Hz), 6.44 (1H, dd, J = 8.3 Hz), 5.66 (1H, t, J = 2.5 Hz), 5.59 (1H, brs), 4.20-4.13 (4H, m), 3.80 (3H , s), 3.73 (3H, s), 1.25 (3H, t, J = 7.1 Hz);

¹³ C NMR (DMSO-d ₆ ) δ ppm ^-1 160.9, 159.6, 158.0, 129.2, 124.0, 120.0, 104.2, 98.3, 95.5, 58.3, 55.4, 55.1, 43.6, 14.7;

MC (ERI) m / z 303 (M-1).

(b) 1- (2,4-Dimethoxybenzyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

The title compound was obtained as a solid in 14% (0.118 g) yield and was prepared according to General Method B using 3 - [(2,4-dimethoxybenzyl) amino] -1H-pyrrol-2- ethyl ester carboxylic acid (0.828 g, 2.72 mmol) and ethoxycarbonyl isothiocyanate (0.31 ml, 2.72 mmol).

¹ H NMR (DMSO-d ₆₎ δ mn ^-1 12.41 (1H, br s), 12.27 (1H, s), 7.27 (1H, t, J = 2.9 Hz), 6.77 (1H, d, J = 8.3 Hz ), 6.61 (1Н, d, J = 2.3 Hz), 6.41 (1Н, dd, J = 8.5, 2.4 Hz), 5.95 (1Н, t, J = 2.3 Hz), 5.54 (2Н, s), 3.88 (3H , s), 3.72 (3H, s);

MC (ERI) m / z 318 (M + 1).

Example 18

1 - [(3-Chloropyridin-2-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) 3 - {[((3-Chloropyridin-2-yl) methyl] amino} -1H-pyrrole-2-carboxylic acid ethyl ester

The title compound was obtained as a solid in 91% (0.225 g) yield and was prepared according to General Method A using 3-amino-1H-pyrrole-2-carboxylic acid ethyl ester (0.231 g, 1.50 mmol) and 3-chloropyridin-2-carbaldehyde (Nadeem Iqbal et al., J. Med. Chem. 1998, 41, 1827-1837) (0.212 g, 1.50 mmol).

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 10.81 (1H, br s), 8.53-8.51 (1H, m), 7.94-7.92 (1H, m), 7.40-7.36 (1H, m), 6.77- 6.76 (1H, m), 5.74-5.73 (1H, m), 4.43 (1H, d, J = 5.5 Hz), 4.20-4.15 (2H, m), 1.30-1.27 (3H, m);

MC (ERI) m / z 280 (M + 1).

(b) 1 - [(3-Chloropyridin-2-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

The title compound was obtained as a solid in 5% (0.011 g) yield and was prepared according to general method B using 3 - {[(3-chloropyridin-2-yl) methyl] amino} -1H ethyl ester -pyrrole-2-carboxylic acid (0.215 g, 0.77 mmol) and ethoxycarbonyl isothiocyanate (0.09 ml, 0.77 mmol).

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 12.26 (1H, br s), 8.32-8.30 (1H, m), 7.96-7.93 (1H, m), 7.34-7.30 (1H, m), 7.28 ( 1H, d, J = 3.0 Hz), 6.16 (1H, d, J = 2.8 Hz), 5.80 (2H, s);

MS (ERI) m / z 293 (M + 1).

Example 19

1 - {[3- (2-Ethoxyethoxy) pyridin-2-yl] methyl} -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) 3- (2-Ethoxyethoxy) -2-methylpyridine

Potassium carbonate (2.20 g, 15.9 mmol) was added to a stirred solution of 3-hydroxy-2-methylpyridine (1.45 g, 13.3 mmol) and 2-chloroethylethyl ether (1.75 ml, 15.9 mmol) ) in DMF (7 ml) and the mixture was stirred at 70 ° C. overnight. The reaction was not completed, an additional amount of 2-chloroethylethyl ether (1 equiv.) And potassium carbonate (1 equiv.) Was added and the mixture was stirred at 85 ° C for 8 hours. Water and ethyl acetate were added and the aqueous layer was extracted with ethyl acetate. The organic layer was dried (MgSO ₄ ), filtered and concentrated. The crude product was purified by flash column chromatography (heptane / ethyl acetate gradient; 0 to 50% ethyl acetate) to give 1.80 g (75%) of the title compound.

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 8.03-7.99 (1H, m), 7.33-7.31 (1H, m), 7.18-7.14 (1H, m), 4.13-4.11 (2H, m), 3.73 -3.71 (2H, m), 3.52 (2H, q, J = 7.0 Hz), 2.35 (3H, s), 1.12 (3H, t, J = 6.9 Hz);

MC (ERI) m / z 182 (M + 1).

(b) 3- (2-Ethoxyethoxy) pyridin-2-carbaldehyde

A mixture of 3- (2-ethoxyethoxy) -2-methylpyridine (0.506 g, 2.79 mmol) and selenium dioxide (0.31 g, 2.79 mmol) in 1,4-dioxane (10 ml) was heated at 75 ° C. during the night. After cooling to room pace. this mixture was filtered and the solids washed with ethyl acetate. The solvent was removed in vacuo. The reaction was not completed, and the solid was dissolved in 1,4-dioxane (15 ml) and selenium dioxide (0.31 g, 2.79 mmol) was added. This mixture was heated at 110 ° C. overnight. Ethyl acetate (10 ml) was added and the mixture was filtered. The black solid was washed with ethyl acetate and the filtrate was evaporated in vacuo. The crude product was purified by flash column chromatography (heptane / ethyl acetate gradient; 0 to 100% ethyl acetate) to give 0.21 g (39%) of the title compound.

¹ H NMR (DMSO-d ₆₎ δ mn ^-1 10.23 (1H, s), 8.35 (1H, d, J = 4.3 Hz), 7.77 (1H, d, J = 8.6 Hz), 7.66-7.62 (1H, m), 4.29 (2H, m), 3.75 (2H, m), 3.55-3.49 (2H, m), 1.14-1.09 (3H, m).

(c) 3 - ({[3- (2-Ethoxyethoxy) pyridin-2-yl] methyl} amino} -1H-pyrrole-2-carboxylic acid ethyl ester

The title compound (0.17 g, 73%) was obtained according to general method A using 3- (2-ethoxyethoxy) pyridine-2-carbaldehyde (0.21 g, 1.08 mmol) and 3- ethyl ester amino-1H-pyrrole-2-carboxylic acid (0.11 g, 0.717 mmol).

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 10.76 (1H, s), 8.13-8.12 (1H, m), 7.46-7.44 (1H, m), 7.30-7.28 (1H, m), 6.76-6.75 (1H, m), 6.29 (1H, br s), 5.71-5.70 (1H, m), 4.32-4.31 (2H, m), 4.22-4.17 (4H, m), 3.77-3.74 (2H, m), 3.57-3.51 (2H, m), 1.30 (3H, t, J = 7.0 Hz), 1.15-1.12 (3H, m);

MS (ERI) m / z 334 (M + 1).

(d) 1 - {[3- (2-Ethoxyethoxy) pyridin-2-yl] methyl} -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-c1] pyrimidin-4-one

The title compound (0.051 g, 28%) was obtained according to General Method B using 3 - ({[3- (2-ethoxyethoxy) pyridin-2-yl] methyl} amino) -1H-pyrrol-2 ethyl ester -carboxylic acid (0.17 g, 0.52 mmol) and ethoxycarbonyl isothiocyanate (0.07 ml, 0.62 mmol).

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 12.32-12.19 (2H, m), 7.92 (1H, d, J = 4.0 Hz), 7.47 (1H, d, J = 7.8 Hz), 7.32-7.14 ( 2H, m), 5.98 (1H, d, J = 2.8 Hz), 5.73 (2H, s), 4.26-4.23 (2H, m), 3.78-3.76 (2H, m), 3.55 (2H, q, J = 7.1 Hz), 1.14 (3H, t, J = 6.9 Hz);

¹³ C NMR (DMSO-d ₆ ) δ 173.5, 152.7, 152.4, 143.7, 140.3, 137.8, 127.7, 123.0, 119.0, 113.5, 96.8, 68.2, 65.8, 49.8, 15.1;

MC (ERI) m / z 347 (M + 1).

Example 20

1 - [(6-Oxo-1,6-dihydropyridin-2-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) 3 - {[(6-oxo-1,6-dihydropyridin-2-yl) methyl] amino} -1H-pyrrole-2-carboxylic acid ethyl ester

b-Oxo-1,6-dihydropyridine-2-carbaldehyde (WO 2002/006272) (0.31 g, 2.5 mmol) was dissolved in EtOH (10 ml). 3-amino-1H-pyrrole-2-carboxylic acid ethyl ester (0.19 g, 1.3 mmol) was added, followed by the addition of HOAc (0.14 ml, 2.5 mmol). This mixture was stirred for 75 minutes at room. pace. and then NaCNBH ₃ (0.16 g, 2.5 mmol) was added. The reaction mixture was stirred at room. pace. during the night. The solvent was evaporated in vacuo and the crude product was purified by flash column chromatography (CH ₂ Cl ₂ / methanol gradient; 0 to 10% methanol) to give 0.288 g (85%) of the title product as an oil which crystallized upon standing .

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 11.57 (1H, br s), 10.77 (1H, br s), 7.34-7.30 (1H, m), 6.71-6.70 (1H, m), 6.16-6.13 (2H, m), 5.98 (1H, br s), 5.75 (1H, s), 5.64-5.63 (1H, m), 4.20 (2H, q, J = 7.1 Hz), 4.09-4.08 (2H, m) 1.27 (3H, t, J = 7.1 Hz);

MS (ERI) m / z 262 (M + 1).

(b) 1 - [(6-Oxo-1,6-dihydropyridin-2-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4- it

Benzoylisothiocyanate (0.27 g, 1.6 mmol) dissolved in CH ₂ Cl ₂ (3 ml) was added to 3 - {[(6-oxo-1,6-dihydropyridin-2-yl) methyl] amino ethyl ester } -1H-pyrrole-2-carboxylic acid (0.25 g, 0.96 mmol) in CH ₂ Cl ₂ (7 ml). The resulting mixture was stirred at room. pace. during the night. The solvent was removed in vacuo, the residue was dissolved in methanol (15 ml) and potassium carbonate (0.50 g, 3.6 mmol) was added. The reaction mixture was stirred at 50 ° C for 6.5 hours. After cooling to room. temp., was added dropwise 1 M HCl until a neutral pH was obtained. The resulting precipitate was collected, washed with methanol and purified by preparative HPLC to give the title compound (0.097 g, 37%) as a solid.

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 12.46-12.38 (2H, m), 11.69 (1H, br s), 7.34-7.29 (2H, m), 6.23 (2H, s), 5.75 (1H, br s), 5.49 (2H, s);

¹³ C NMR (DMSO-d ₆ ) δ 173.6, 162.7, 152.5, 140.6, 136.7, 128.0, 113.6, 96.6;

MS (ERI) m / z 275 (M + 1).

Example 21

1- (1H-Indol-3-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) Ethyl 3 - [(1H-indol-3-ylmethyl) amino] -1H-pyrrole-2-carboxylate

The reaction mixture of 3-amino-1H-pyrrol-2-carboxylic acid ethyl ester (0.075 g, 0.49 mmol), indole-3-carboxaldehyde (0.085 g, 0.58 mmol), NaCNBH ₃ (0.031 g, 0.49 mmol) and HOAc (0.056 ml, 0.97 mmol) in methanol (3 ml) were stirred at room temperature. pace. during the night. This mixture was concentrated in vacuo and the crude product mixture was used in the next step without further purification.

MS (ERI) m / z 284 (M + 1).

(6) 1- (1H-Indol-3-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

The crude mixture of ethyl 3 - [(1H-indol-3-ylmethyl) amino] -1H-pyrrole-2-carboxylate (maximum 0.49 mmol) was added to CH ₂ Cl ₂ (5 ml). A few drops of methanol were added to increase solubility. Benzoylisothiocyanate (0.072 g, 0.53 mmol) was added and the mixture was stirred at room temperature. pace. for 1 h. This mixture was concentrated in vacuo. Ammonia was added (7 N in methanol, 3 ml) and the mixture was heated at 80 ° C. for 2 hours. This mixture was concentrated and purified by preparative HPLC to give the title compound (0.030 g, 21%) as a solid .

¹ H NMR (DMSO-d ₆₎ δ 12.13 mn ^-1 (2H, br s), 11.08 (1H , s), 7.87 ( 1H, d, J = 8.1 Hz), 7.54-7.47 (1H, m), 7.38 -7.30 (1H, m), 7.29-7.25 (1H, m), 7.10-7.03 (1H, m), 7.01-6.93 (1H, m), 6.33 (1H, d, J = 2.8 Hz), 5.88 (2H , s);

¹³ C NMR (DMSO-d ₆ ) δ ppm ^-1 173.14, 152.86, 136.71, 136.42, 128.02, 126.45, 125.83, 121.61, 119.67, 119.16, 114.36, 111.95, 109.51, 97.74, 46.31;

MS (ERI) m / z 295 (M-1).

Example 22

1- (1H-Benzimidazol-2-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) Ethyl 3 - [(1H-benzimidazol-2-ylmethyl) amino] -1H-pyrrole-2-carboxylate

The reaction mixture of 3-amino-1H-pyrrole-2-carboxylic acid ethyl ester (0.77 g, 4.99 mmol), 1H-benzimidazole-2-carboxaldehyde (0.88 g, 5.99 mmol), NaCNBH ₃ ( 0.31 g, 4.99 mmol) and HOAc (0.57 ml, 9.99 mmol) in methanol (15 ml) were stirred at room temperature. pace. during the night. This mixture was then heated at 50 ° C for 5 hours, cooled to room. pace. and evaporated in vacuo. The residue was dissolved in ethyl acetate and washed with water. The aqueous phase was extracted with ethyl acetate (twice). The combined organic layers were dried (MgSO ₄ ) and concentrated. The crude product was purified by flash column chromatography (heptane / ethyl acetate (1: 0 to 0: 1) to obtain 1.15 g (81%) of the title compound.

¹ H NMR (DMSO-de) δ ppm ^-1 12.27 (1H, s), 10.85 (1H, s), 7.63-7.37 (2H, m), 7.17-7.08 (2H, m), 6.71 (1H, t, J = 3.0 Hz), 5.99 (1H, br s), 5.60 (1H, t, J = 2.7 Hz), 4.48 (2H, d, J = 5.8 Hz), 4.22 (2H, q, J = 7.1 Hz), 1.29 (3H, t, J = 7.1 Hz);

MC (ERI) m / z 285 (M + 1).

(b) 1- (1H-Benzimidazol-2-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

Ethyl 3 - [(1H-benzimidazol-2-ylmethyl) amino] -1H-pyrrole-2-carboxylate (0.33 g, 1.16 mmol) was added to CH ₂ Cl ₂ (3 ml) and methanol was added while did not receive a clear solution. This solution was stirred at room. pace. within 1 h. Benzoylisothiocyanate (0.73 ml, 0.46 mmol) was added and the mixture was concentrated after stirring at room temperature. pace. within 30 minutes. The residue was dissolved in ammonia (7N in methanol, 7 ml) and the mixture was heated at 80 ° C in a sealed steel container for 2 hours. After cooling to room. pace. the precipitated product was filtered and washed with methanol, diethyl ether and ethyl acetate to obtain 0.23 g (66%) of the title compound as a white solid.

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 12.27 (3H, brs), 7.61-7.37 (2H, m), 7.43-7.27 (1H, m), 7.18-7.07 (2H, m), 6.19 (1H , d, J = 2.8 Hz), 5.89 (2H, s);

MS (ERI) m / z 298 (M + 1).

Example 23

1 - [(5-Chloro-1H-indol-2-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

5-Chloro-1H-indole-2-carbaldehyde (0.15 g, 0.76 mmol), NaCNBH ₃ (0.040 g, 0.63 mmol) and Et ₃ N (0.088 ml, 0.63 mmol) were added to the stirred a solution of 3-amino-1H-pyrrol-2-carboxylic acid ethyl ester hydrochloride (0.12 g, 0.63 mmol) in methanol (3 ml). The resulting mixture was stirred at room. pace. during the night. The reaction mixture was heated to 50 ° C. Additional NaCNBH ₃ (0.5 equiv.) Was added and the mixture was stirred at 50 ° C. for 3 hours. A few drops of HOAc were added and after 1 hour the reaction medium was cooled to rt. pace. and concentrated in vacuo. The residue was dissolved in CH ₂ Cl ₂ (2 ml) and methanol (2 ml). Benzoylisothiocyanate (0.093 ml, 0.69 mmol) was added and after stirring at room temperature. pace. for 1 h, this mixture was concentrated in vacuo. The residue was dissolved in ammonia (7N in methanol, 3 ml) and heated at 80 ° C for 2 hours. The precipitated product was filtered and washed with methanol and diethyl ether, followed by purification by preparative HPLC to obtain 0.063 g (30%) of the compound. indicated in the title, as a solid.

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 12.41 (2H, br s), 11.51-11.04 (1H, m), 7.51-7.46 (1H, m), 7.40-7.33 (1H, m), 7.33- 7.30 (1H, m), 7.07-6.99 (1H, m), 6.34-6.27 (2H, m), 5.87-5.80 (2H, m);

¹³ C NMR (DMSO-de) 5 ppm ^-1 173.65, 153.05, 136.84, 135.98, 134.74, 129.28, 128.27, 123.97, 121.26, 119.19, 114.24, 113.25, 100.33, 97.17, 47.31;

MS (ERI) m / z 331 (M + 1).

Example 24

1 - [(5-Fluoro-1H-indol-2-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

The title compound was obtained as a solid in 19% (0.038 g) yield and was prepared according to the general method from Example 23 using 3-amino-1H-pyrrol-2-carboxylic acid ethyl ester hydrochloride (0.12 g, 0.63 mmol), 5-Fluoro-1H-indole-2-carbaldehyde (0.12 g, 0.76 mmol), MASMBH (0.040 g, 0.63 mmol, +0.5 equiv.), Et ₃ N (0.088 ml, 0.63 mmol) and benzoylisothiocyanate (0.093 ml, 0.69 mmol).

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 12.38 (2H, br s), 11.10 (1H, s), 7.41-7.26 (2H, m), 7.25-7.11 (1H, m), 6.96-6.79 ( 1H, m), 6.37-6.24 (2H, m), 5.83 (2H, s);

¹³ C NMR (DMSO-d ₆ ) δ ppm ^-1 173.61, 173.81, 158.46, 156.17, 152.94, 136.85, 136.10, 132.94, 128.39, 128.30, 114.19, 112.71, 112.61, 109.54, 109.28, 104.75, 104.51, 100.82, 100.78 , 97.23, 47.35;

MS (ERI) m / z 315 (M + 1).

Example 25

1- (1H-Indol-6-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

The title compound was obtained as a solid in 19% (0.035 g) yield and was prepared according to the general method from Example 23 using 3-amino-1H-pyrrol-2-carboxylic acid ethyl ester hydrochloride (0.12 g, 0.63 mmol), 6-formylindole (0.11 g, 0.76 mmol), MASMVNz (0.040 g, 0.63 mmol, +0.5 equiv.), Et ₃ N (0.088 ml, 0, 63 mmol) and benzoylisothiocyanate (0.0993 ml, 0.69 mmol).

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 12.37 (2H, br s), 11.01 (1H, s), 7.53-7.43 (1H, m), 7.33 (1H, s), 7.32-7.25 ( 2H, m), 7.09-7.03 (1H, m), 6.41- 6.34 (1H, m), 6.17 (1H, d, J = 2.8 Hz), 5.79 (2H, s);

¹³ C NMR (DMSO-d ₆ ) δ ppm ^-1 173.76, 152.91, 137.06, 136.21, 128.88, 128.27, 127.31, 125.99, 120.35, 118.91, 114.16, 110.24, 101.28, 97.63, 53.32;

MS (ERI) m / z 297 (M + 1).

Example 26

1- (1H-Indol-5-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

The title compound was obtained as a solid in 39% (0.073 g) yield and was prepared according to the general method from Example 23 using 3-amino-1H-pyrrol-2-carboxylic acid ethyl ester hydrochloride (0.12 g, 0.63 mmol), 5-formylindole (0.11 g, 0.76 mmol), NaCNBH ₃ (0.040 g, 0.63 mmol, +0.5 equiv.), Et ₃ N (0.088 ml, 0 63 mmol) and benzoylisothiocyanate (0.093 ml, 0.69 mmol).

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 12.33 (2H, br s), 11.07 (1H, s), 7.52 (1H, s), 7.36-7.29 (2H, m), 7.29-7.25 (1H, m), 7.21-7.12 (1H, m), 6.39-6.34 (1H, m), 6.21-6.16 (1H, m), 5.77 (2H, s);

¹³ C NMR (DMSO-d ₆ ) δ ppm ^-1 173.32, 152.51, 136.63, 135.20, 127.83, 127.50, 126.15, 125.81, 120.54, 118.81, 113.82, 111.40, 101.00, 97.28, 52.99;

MS (ERI) m / z 297 (M + 1).

Example 27

1 - [(5-Fluoro-1H-indol-3-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

3-amino-1H-pyrrole-2-carboxylic acid ethyl ester hydrochloride (0.10 g, 0.52 mmol) was dissolved in methanol (4 ml) and 5-Fluoro-1H-indole-3-carboxaldehyde (0.10) was added. g, 0.63 mmol), NaCNBH ₃ (0.033 g, 0.52 mmol) and Et ₃ N (0.073 g, 0.52 mmol). The resulting mixture was stirred at room. pace. during the night. Additional NaCNBH ₃ (0.01 g) was added and the mixture was heated at 50 ° C. for 5 hours. The reaction mixture was cooled to room temperature. pace. and concentrated in vacuo. The crude intermediate was dissolved in CH ₂ Cl g (3 ml) and methanol (1 ml). Benzoylisothiocyanate (0.078 ml, 0.58 mmol) was added and after stirring at room temperature. pace. for 1 h, this mixture was concentrated in vacuo. The residue was dissolved in ammonia (7N in methanol, 3 ml) and heated at 80 ° C for 2 hours. The solvent was removed in vacuo and after purification by preparative HPLC, the title compound (0.035 g, 21%) was obtained as solid matter.

¹ H NMR (DMSO-d ₆₎ δ 12.29 mn ^-1 (2H, s), 11.38-11.08 (1H, m), 7.76-7.68 (1H, m), 7.65-7.59 (1H, m), 7.37-7.30 (1H, m), 7.30-7.27 (1H, m), 6.96-6.86 (1H, m), 6.37 (1H, d, J = 2.81-H), 5.84 (2H, s);

¹³ C NMR (DMSO-d ₆ ) δ ppm ^-1 173.09, 158.27, 155.97, 152.81, 136.59, 133.11, 128.14, 128.09, 126.70, 126.59, 114.37, 113.01, 112.91, 109.95, 109.91, 109.86, 109.68, 104.70, 104.46 97.74, 46.10;

MS (ERI) m / z 315 (M + 1).

Example 28

1- (1H-Imidazol-5-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

3-amino-1H-pyrrole-2-carboxylic acid ethyl ester hydrochloride (0.10 g, 0.52 mmol) was dissolved in methanol (4 ml) and 4-formylimidazole (0.060 g, 0.63 mmol), NaCNBH _{3 was} added. (0.033 g, 0.52 mmol) and Et ₃ N (0.073 g, 0.52 mmol). The resulting mixture was stirred at room. pace. during the night. The solvent was removed in vacuo and the residue was dissolved in CH ₂ Cl ₂ (3 ml) and methanol (1 ml). Benzoylisothiocyanate (0.078 ml, 0.58 mmol) was added and after stirring at room temperature. pace. for 30 minutes this mixture was concentrated in vacuo. The residue was dissolved in ammonia (7N in methanol, 3 ml) and heated at 80 ° C for 1 h. The precipitated product was filtered and washed with methanol, followed by washing with diethyl ether. The crude product was purified by preparative HPLC to give 0.017 g (13%) of the title compound as a solid.

OS 710/07

¹ H NMR (DMSO-d ₆₎ δ 12.49-11.78 mn ^-1 (SH, m), 7.53 (1H, s), 7.30 (1H, d, J = 2.8 Hz), 7.05 (1H, s), 6.36 ( 1H, d, J = 3.0 Hz), 5.54 (2H, s);

MC (ERI) m / z 335 (M + 1).

Example 29

1- (1H-Imidazol-2-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) Ethyl 3 - [(1H-imidazol-2-ylmethyl) amino] -1H-pyrrole-2-carboxylate

The reaction mixture with 3-amino-1H-pyrrole-2-carboxylic acid ethyl ester (0.2 g, 1.30 mmol), 2-imidazole carboxaldehyde (0.15 g, 1.53 mmol), NaCNBH ₃ (0.082 g, 1.30 mmol) and ONac (0.15 ml, 2.60 mmol) in methanol (5 ml) were stirred at room temperature. pace. for 2 hours. The solvent was evaporated in vacuo and the residue was dissolved in ethyl acetate, washed with water and the aqueous layer was extracted twice with ethyl acetate. The combined organic layers were dried (MgSO ₄ ), filtered and concentrated. The crude product was purified by flash column chromatography (gradient CH ₂ Cl ₂ / methanol; 0 to 20% methanol) to give 0.30 g (99%) of the title compound.

¹ H NMR (DMSO-d ₆₎ δ mn ^-1 10.84 (1H, br s), 7.03 (2H, s), 6.79-6.64 (1H, m), 5.76 (1H, br s), 5.68-5.57 (1H , m), 4.29 (2H, d, J = 5.8 Hz), 4.19 (2H, q, J = 7.1 Hz), 3.16 (1H, s), 1.26 (3H, t, J = 7.1 Hz);

MS (ERI) m / z 235 (M + 1).

(b) 1- (1H-Imidazol-2-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

Benzoylisothiocyanate (0.19 ml, 1.41 mmol) was added to a stirred solution of ethyl 3 - [(1H-imidazol-2-ylmethyl) amino] -1H-pyrrole-2-carboxylate (0.3 g, 1.28 mmol) ) in CH ₂ Cl ₂ (4 ml) and methanol (2 ml) and this mixture was stirred at room. pace. for 1 h. The solvent was evaporated in vacuo and the residue was dissolved in ammonia (7 N in methanol, 7 ml) and heated at 80 ° C for 1 h. The crude product was filtered and purified by preparative HPLC to obtain 0.110 g (35%) the title compound as a white solid.

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 12.46-12.14 (2H, m), 11.81 (1H, brs), 7.28 (1H, d, J = 2.5 Hz), 6.99 (1H, s), 6.79 ( 1H, s), 6.13 (1H, d, J = 2.8 Hz), 5.67 (2H, s);

MS (ERI) m / z 248 (M + 1).

Example 30

1 - [(5-Chloro-1H-benzimidazol-2-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) Ethyl 3 - {[(5-chloro-1H-benzimidazol-2-yl) methyl] amino} -1H-pyrrole-2-carboxylate

The reaction mixture of 3-amino-1H-pyrrol-2-carboxylic acid ethyl ester (0.077 g, 0.5 mmol), NaCNBH ₃ (0.057 g, 0.9 mmol) and HOAc (0.030 g, 0.5 mmol) in methanol (4 ml) was stirred at room. pace. for 5 minutes before adding 5-chloro-1H-benzimidazole-2-carbaldehyde (0.144 g, 0.8 mmol) followed by adding CH ₂ Cl ₂ (1 ml) and DMF (0.4 ml). The resulting mixture was allowed to stir for 16 hours at room temperature. pace. in an atmosphere of nitrogen. Additional 5-chloro-1H-benzimidazole-2-carbaldehyde (0.030 g) and NaCNBH ₃ (0.015 g) were added and the reaction mixture was stirred for 4 hours. This reaction mixture was neutralized with 2 M NaOH and diluted with ethyl acetate. It was extracted with water and the organic layer was dried (Na ₂ SO ₄ ) and concentrated. The crude product was purified by flash column chromatography (heptane / ethyl acetate gradient; 0 to 100% ethyl acetate) to give 0.074 g (46%) of the title product.

¹ H NMR (CDCl ₃₎ δ 8.28 mn ^-1 (1H, br s), 7.52 (1H , s), 7.44 (1H, d, J = 2.0 Hz), 7.22 (1H, d, J = 2.0 Hz); 6.66 (1H, s), 5.61 (1H, t, J = 2.4 Hz), 4.67 (2H, s), 4.27 (2H, m), 1.33 (3H, t, J = 6.8 Hz);

MC (ERI) m / z 319 (M + 1).

(b) 1 - [(5-Chloro-1H-benzimidazol-2-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

A solution of ethyl 3 - {[(5-chloro-1H-benzimidazol-2-yl) methyl] amino} -1H-pyrrole-2-carboxylate (0.074 g, 0.23 mmol) in CH ₂ Cl _{2 was} stirred for 5 minutes. To increase solubility, DMF (0.2 ml) was added. Benzoylisothiocyanate (0.045 g, 0.28 mmol) was added and the mixture was stirred for 1 h, then concentrated in vacuo. The crude intermediate was dissolved in ammonia (7 N in methanol, 2 ml) and stirred at 70 ° C. for 1.5 hours in a sealed vessel. After cooling to room pace. the precipitated product was collected by vacuum filtration, washed with diethyl ether and dried, yielding 0.033 g (43%) of the title product as a white solid.

¹ H NMR (DMSO-d ₆₎ δ 12.33 mn ^-1 (3H, br s), 7.48 (2H , m), 7.32 (1H, s), 7.17 (1H, d, J = 8.0 Hz), 6.21 (1H , s), 5.88 (2H, s);

MC (ERI) m / z 332 (M + 1).

Example 31

1 - [(4,5-Dimethyl-1H-benzimidazol-2-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) 4,5-Dimethyl-1H-benzimidazole-2-carbaldehyde 3,4-Dimethylbenzene-1,2-diamine (0.409 g, 3.0 mmol) and dichloroacetic acid (0.768 g, 6.0 mmol) in 4 n HCl (10 ml) was heated at 100 ° C for two days. After cooling to room pace. this mixture was filtered and the mother liquor was extracted with chloroform (4 times). The pH was adjusted to 12 using 2 M NaOH, and the resulting white precipitate was collected by filtration. The crude product was used in the next step without further purification.

MC (ERI) m / z 175 (M + 1).

(b) Ethyl 3 - {[(4,5-dimethyl-1H-benzimidazol-2-yl) methyl] amino} -1H-pyrrole-2-carboxylate

3-amino-1H-pyrrole-2-carboxylic acid ethyl ester (0.077 g, 0.5 mmol), 4,5-dimethyl-1H-benzimidazole-2-carbaldehyde (0.130 g, 0.75 mmol) and HOAc (0.045 g, 0.75 mmol) was stirred in methanol (4 ml), followed by the addition of NaCNBH ₃ . The resulting mixture was stirred at room. pace. within 16 hours. The reaction mixture was neutralized with 2 M NaOH and the solvent was removed in vacuo. The residue was dissolved in ethyl acetate and extracted with water. The organic layer was dried (Na ₂ SO ₄ ) and concentrated. The crude product was purified by flash column chromatography (heptane / ethyl acetate gradient; 0 to 100% ethyl acetate) to give a white solid, 0.043 g (27%) of the title compound as a mixture of tautomers (1: 1).

¹ H NMR (DMSO-d ₆₎ δ mn ^-1 12.15 (1H, s), 12.04 (1H, s), 10.81 (2H, s), 7.26 (1H, d, J = 8.4 Hz), 7.12 (1H, d = 8.0 Hz), 6.94 (2H, d, J = 8.4 Hz), 6.72 (2H, s), 5.93 (2H, s), 5.70 (1H, s), 5.61 (1H, s), 4.44 (4H, dd, J = 9.2, 6.0 Hz), 4.22 (4H, m), 2.44 (3H, s), 2.37 (3H, s), 2.29 (6H, s), 1.30 (6H, m);

MS (ERI) m / z 313 (M + 1).

(c) 1 - [(4,5-Dimethyl-1H-benzimidazol-2-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4- it

Ethyl 3 - {[(4,5-dimethyl-1H-benzimidazol-2-yl) methyl] amino} -1H-pyrrole-2-carboxylate (0.043 g, 0.14 mmol) was dissolved in CH ₂ Cl ₂ (1 5 ml) and benzoylisothiocyanate (0.026 g, 0.16 mmol) was added. After stirring at room pace. within 1 h, the solvent was removed in vacuo. The residue was dissolved in ammonia (7N in methanol) and heated to 70 ° C for 2 hours in a sealed vessel. The solvent was removed in vacuo and the residue was purified by preparative HPLC to give a white solid, 0.008 g (18%) of the title compound as a mixture of tautomers (1: 1).

¹ H NMR (DMSO-d ₆₎ δ 12.18 mn ^-1 (2H, s), 11.98 (2H, s), 7.28 (2H, t, J = 2.4 Hz), 7.19 (1H, d, J = 8.0 Hz) , 7.08 (1H, d, J = 8.0 Hz), 6.92 (2H, t, J = 8.0 Hz), 6.14 (2H, dd, J = 8.0, 2.8 Hz), 5.89 (2H, s), 5.86 (2H, s), 2.41 (3H, s), 2.37 (3H, s), 2.29 (3H, s), 2.28 (3H, s);

MC (ERI) m / z 326 (M + 1).

Example 32

7-Bromo-1-isobutyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) 3-amino-4-bromo-1H-pyrrole-2-carboxylic acid ethyl ester

3-amino-1H-pyrrole-2-carboxylic acid ethyl ester (0.92 g, 0.6 mmol) was dissolved in HOAc (1 ml) and bromine water (0.96 g, 0.6 mmol) was added. This mixture was stirred at room. pace. for 1 h, the resulting white precipitate was collected by filtration and washed with diethyl ether. The title compound (0.136 g, 97%) was obtained as a white solid and was used in the next step without further purification.

¹ H NMR (DMSO-d ₆₎ δ mn ^{-1 11.67 (1H, s),} 7.05 (1H, s), 6.02 ( 2H, br s), 4.25 (2H, q, J = 7.2 Hz), 1.28 (3H , t, J = 7.2 Hz);

MC (ERI) m / z 233 (M + 1).

(b) 4-Bromo-3- (isobutylamino) -1H-pyrrole-2-carboxylic acid ethyl ester

3-amino-4-bromo-1H-pyrrole-2-carboxylic acid ethyl ester (0.136 g, 0.58 mmol) and isobutyraldehyde (0.067 g, 0.93 mmol) were stirred in CH ₂ Cl ₂ / MeOH (1: 1 , 3 ml) at room pace. within 2 hours. NaCNBH ₃ (0.065 g, 1.04 mmol) and HOAc (0.035 g, 0.58 mmol) were added, the mixture was stirred at room temperature. pace. for 2 hours and then stirred at 50 ° C. for 16 hours. An additional amount of isobutyraldehyde (1 equiv.) and NaCNBH ₃ (0.5 equiv.) were added and stirring of this mixture was continued at 50 ° C. overnight. The reaction mixture was neutralized with a solution of 2 M NaOH and the solvents were removed in vacuo. The precipitate was dissolved in ethyl acetate and extracted with water. The organic layer was dried (Na ₂ SO ₄ ) and concentrated. The crude product was purified by flash chromatography (heptane / ethyl acetate gradient, 0 to 30% ethyl acetate) to give the title compound (0.040 g, 24%) as a white solid.

¹ H NMR (CDCl ₃₎ δ 6.75 mn ^-1 (1H, s), 4.32 (2H, q, J = 7.2 Hz), 3.28 (2H, d, J = 6.8 Hz), 1.85 (1H, m), 1.35 (3H, t, J = 7.2 Hz), 0.97 (3H, d, J = 6.8 Hz);

MS (ERI) m / z 289 (M + 1).

(c) 7-Bromo-1-isobutyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

Benzoylisothiocyanate (0.034 g, 0.2 mmol) was added to a solution of 4-bromo-3- (isobutylamino) -1H-pyrrole-2-carboxylic acid ethyl ester (0.050 g, 0.17 mmol) in CH ₂ Cl ₂ and the resulting mixture stirred at room pace. for 1 h before concentration in vacuo. The residue was dissolved in ammonia (7 M in methanol, 1.5 ml) and stirred at 70 ° C for 4 hours. An additional amount of ammonia (7 M in methanol, 1 ml) was added and the mixture was stirred for 80 hours at 5 ° C. This mixture was cooled to room. pace. and the precipitated product was filtered and washed with diethyl ether. Recrystallization with methanol gave the title compound (0.028 g, 55%) as a white solid.

¹ H NMR (DMSO-d ₆₎ δ 12.57 mn ^-1 (2H, brs), 7.58 (1H, s), 4.92 (1H, brs), 4.42 (1H, brs), 2.39 (1H, m), 0.94 ( 6H, d, J = 6.4 Hz);

MC (ERI) m / z 303 (M + 1).

Example 33

1- (3-Chlorophenyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

(a) Ethyl 3 - [(3-chlorophenyl) amino] -1H-pyrrole-2-carboxylate

A mixture of 3-amino-1H-pyrrole-2-carboxylic acid ethyl ester (0.20 g, 1.3 mmol), 3-bromochlorobenzene (0.30 g, 1.6 mmol), Pd ₂ (dba) ₃ (0.048 g, 0.052 mmol), rat. Β-BINAP (0.048 g, 0.078 mmol) and cesium carbonate (0.59 g, 1.8 mmol) were heated at 100 ° C in a sealed vessel for microwave irradiation in a nitrogen atmosphere overnight. Additional Pd ₂ (dba) ₃ (0.10 g, 0.11 mmol) and RS-BINAP (0.11 g, 0.18 mmol) were added and stirring of the reaction mixture was continued overnight at 100 ° C. Additional 3-bromochlorobenzene (0.15 g), Pd ₂ (dba) ₃ (0.098 g) and R, S-BINAP (0.098 g) were added and stirring of the reaction mixture at 100 ° C. continued for another three days. The reaction mixture was poured into ethanol and the resulting solution was filtered. The filtrate was evaporated in vacuo and the residue was purified by flash column chromatography (heptane / ethyl acetate gradient; 0 to 30% ethyl acetate) to give 0.052 g (15%) of the title compound.

¹ H NMR (CDCl ₃ ) δ ppm ^-1 8.42 (1H, br s), 7.17 (1H, t, J = 8.0 Hz), 7.14 (1H, t, J = 2.0 Hz), 6.96-6.94 (1H, m ), 6.87-6.84 (1Н, m), 6.82 (1Н, t, J = 3.0 Hz) ', 6.32 (1Н, t, J = 3.0 Hz), 4.35 (2Н, q, J = 7.2 Hz), 1.38 ( 3H, t, J = 7.1 Hz);

MS (ERI) m / z 263 (M-1).

(b) 1- (3-Chlorophenyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one

Benzoylisothiocyanate (0.035 g, 0.22 mmol) in CH ₂ Cl ₂ (0.5 ml) was added to ethyl 3 - [(3-chlorophenyl) amino] -1H-pyrrole-2-carboxylate (0.052 g, 0.20 mmol) in CH ₂ Cl ₂ (0.5 ml). This mixture was stirred at room. pace. during the night. Additional benzoylisothiocyanate (0.035 g + 0.035 g + 0.035 g) was added over a period of 6 hours, and stirring was continued for 3 days at 50 ° C. The solvent was removed in vacuo and the residue was dissolved in ammonia (7N in methanol, 4 ml). The reaction mixture was heated at 50 ° C. for 2 hours. The crude product was purified by preparative chromatography to give 0.009 g (15%) of the title compound as a solid.

¹ H NMR (DMSO-d ₆ ) δ ppm ^-1 12.41 (2H, br s), 7.60-7.57 (3H, m), 7.41-7.37 (1H, m), 7.25 (1H, d, J = 2.8 Hz) 5.36 (1H, d, J = 2.8 Hz);

¹³ C NMR (DMSO-d ₆ ) δ ppm ^-1 173.8, 152.8, 141.5, 137.9, 133.5, 131., 3 129.0, 128.6, 127.7, 127.3, 113.3.96.7;

MC (ERI) m / z 278 (M + 1).

Screenings

Methods for determining MPO inhibition activity are disclosed in patent application WO 02/090575. The pharmacological activity of the compounds of the invention was tested in the following screening, in which the compounds were tested either individually or in the presence of added tyrosine:

Assay buffer: 20 mM sodium / potassium phosphate buffer, pH 6.5, containing 10 mM taurine and 100 mM NaCl.

Developing reagent: 2 mM 3.3 ', 5.5'-tetramethylbenzidine (TMB), 200 μM KI, 200 mM acetate buffer, pH 5.4, with 20% DMF.

To 10 μl of diluted compounds in the assay buffer, 40 μl of human MPO (final concentration 2.5 nM) containing or not containing 20 μM tyrosine (final concentration, if present, 8 μM) was added, and this mixture was incubated for 10 minutes at ambient temperature. Then, 50 μl of H ₂ O ₂ (final concentration of 100 μM) or only assay buffer as a control was added. After incubation for 10 minutes at ambient temperature, the reaction was stopped by adding 10 μl of 0.2 mg / ml of catalase (final concentration of 18 μg / ml). The reaction mixture was left for an additional 5 minutes before adding 100 μl of TMB developing reagent. Then, the amount of oxidized 3,3 ′, 5,5′-tetramethylbenzidine formed was measured after about 5 minutes using absorption spectroscopy at about 650 nm. HKso values were then determined using standard techniques.

When tested in at least one embodiment of the above screening, the compounds of Examples 1-32 gave IC ₅₀ values of less than 60 μM, indicating that they are expected to show useful therapeutic activity. Representative results are shown in the following Table.

Compound MPO inhibition (in the presence of tyrosine) IC ₅₀ , μM Example 2 0.26 Example 5 0.22 Example 11 1,1

Claims (22)

1. The compound of formula (I)

its tautomer or a pharmaceutically acceptable salt of any of them,
Where:
at least one of X and Y represents S and the other represents O;
L is C _1-7 alkylene, optionally including a heteroatom selected from O, wherein said alkylene is optionally substituted with one or more substituents independently selected from OH, C _1-6 alkyl and C _1-6 alkoxy;
R ¹ represents hydrogen or
1) a partially unsaturated 6-membered ring comprising one heteroatom selected from N, and optionally including a carbonyl group; or
2) an aromatic ring system selected from:
phenyl
a monocyclic 5- or 6-membered heteroaromatic ring structure containing 1-2 heteroatoms selected from N, and
a bicyclic heteroaromatic ring structure containing a 5- or 6-membered heterocycle containing 1-2 heteroatoms selected from N, wherein said heterocycle is fused to a benzene ring,
wherein said aromatic ring system is optionally substituted with one or more substituents independently selected from halogen, OH, C _1-7 alkyl, C _1-7 alkoxy; wherein said alkoxy is optionally further substituted with C _1-6 alkoxy; and wherein said alkyl is optionally further substituted with hydroxy or C _1-6 alkoxy;
R ¹² represents hydrogen;
with the proviso that said compound is not 1- (2-isopropoxyethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one:

2. The compound of claim 1, wherein R ¹ is hydrogen. 3. The compound of claim 1, wherein X is S and Y is O. 4. The compound of claim 1, wherein Y is S and X is O. 5. The compound according to any one of paragraphs. 1-4, where L is C _1-7 alkylene, wherein said alkylene is optionally substituted with one or more C _1-6 alkoxy. 6. The compound of claim 1, wherein L is C _1-3 alkylene, optionally substituted with one or more C _1-6 alkoxy. 7. The compound of claim 1, wherein R ¹ is an aromatic ring system selected from:
phenyl and
a five- or six-membered heteroaromatic ring containing 1-2 heteroatoms selected from N,
wherein said aromatic ring is optionally substituted with one or more substituents independently selected from halogen, C _1-6 alkyl and C _1-6 alkoxy, wherein said alkoxy is optionally further substituted with C _1-6 alkoxy. 8. The compound of claim 1, wherein L is C _1-3 alkylene and R ¹ is a partially unsaturated 6-membered ring comprising one heteroatom selected from N and optionally including a carbonyl group. 9. The compound of claim 1, wherein L is C _1-3 alkylene and R ¹ is an aromatic ring system selected from: phenyl and
a five- or six-membered heteroaromatic ring containing 1-2 heteroatoms selected from N,
wherein said aromatic ring is optionally substituted with one or more substituents independently selected from halogen, C _1-6 alkyl and C _1-6 alkoxy, wherein said alkoxy is optionally further substituted with C _1-6 alkoxy. 10. The compound of claim 1, wherein X is S, Y is O, L is C _1-3 alkylene, and R ¹ is optionally substituted phenyl. 11. The compound of claim 1, wherein X is S, Y is O, L is C _1-3 alkylene, and R ¹ is optionally substituted pyridyl. 12. The compound of claim 1, wherein X is S, Y is O, L is C _1-3 alkylene, which is optionally substituted with C _1-6 alkoxy, and R ¹ is hydrogen. 13. The compound is:
1-butyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1-isobutyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1- (pyridin-2-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1- (2-fluoro-benzyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1- [2- (2-methoxyethoxy) -3-propoxybenzyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1- (6-ethoxy-pyridin-2-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1-piperidin-3-ylmethyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1-butyl-4-thioxo-1,3,4,5-tetrahydro-2H-pyrrolo [3,2-d] pyrimidin-2-one;
1- (2-methoxy-2-methylpropyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1- (2-ethoxy-2-methylpropyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1- (piperidin-4-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1 - [(1-methylpiperidin-3-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1- [2-hydroxy-2- (4-methoxyphenyl) ethyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1- (2-methoxybenzyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1- (3-methoxybenzyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1- (2,4-dimethoxybenzyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1 - [(3-chloropyridin-2-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1 - {[3- (2-ethoxyethoxy) pyridin-2-yl] methyl} -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1 - [(6-oxo-1,6-dihydropyridin-2-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1- (1H-indol-3-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1- (1H-benzimidazol-2-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1 - [(5-chloro-1H-indol-2-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1 - [(5-fluoro-1H-indol-2-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1- (1H-indol-6-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1- (1H-indol-5-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1 - [(5-fluoro-1H-indol-3-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1- (1H-imidazol-5-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1- (1H-imidazol-2-ylmethyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1 - [(5-chloro-1H-benzimidazol-2-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
1 - [(4,5-dimethyl-1H-benzimidazol-2-yl) methyl] -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one;
7-bromo-1-isobutyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one; and
1- (3-chlorophenyl) -2-thioxo-1,2,3,5-tetrahydro-pyrrolo [3,2-d] pyrimidin-4-one,
and their pharmaceutically acceptable salts. 14. The compound of formula (I) according to any one of paragraphs. 1-13, or a pharmaceutically acceptable salt thereof, having the properties of an inhibitor of the myeloperoxidase enzyme (MPO), for use as a medicine. 15. A pharmaceutical composition having the properties of an inhibitor of the myeloperoxidase enzyme (MPO), containing the compound of formula (I) according to any one of paragraphs. 1-13 or a pharmaceutically acceptable salt thereof in a therapeutically effective amount in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier. 16. A method of inhibiting the myeloperoxidase enzyme (MPO), comprising administering a therapeutically effective amount of a compound of formula (I), as defined in any one of claims. 1-13, or a pharmaceutically acceptable salt thereof. 17. The use of the compounds of formula (I) as defined in any one of paragraphs. 1-13, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of diseases or conditions in which inhibition of the MPO enzyme is useful. 18. The use of the compounds of formula (I) as defined in any one of paragraphs. 1-13, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of neuroinflammatory disorders. 19. The use of claim 18, wherein said neuro-inflammatory disorder is multiple sclerosis. 20. The use of claim 17, wherein said disease or disorder is atherosclerosis. 21. The use of claim 17, wherein said disease or disorder is a chronic obstructive pulmonary disease (COPD). 22. A method for producing a compound of formula (I) as defined in any one of claims. 1-10, or a pharmaceutically acceptable salt thereof, comprising a step of reacting a compound of formula (II)

where R ¹ , L and R ¹² are as defined in claim 1, and R is C _1-6 alkoxy; with C _1-6 alkoxycarbonylisothiocyanate or phenylcarbonylisothiocyanate; and, where necessary, converting the resulting compound of formula (I) or another salt thereof into a pharmaceutically acceptable salt thereof.